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Abstract 
The PI3K/PTEN signalling pathway plays an important role in regulation of 
cell growth, survival, metabolism and migration in many different types of 
cells. Aberrations in this pathway have implications in metabolic and hyper-
proliferative disorders such as diabetes and cancer. PTEN is a tumour 
suppressor found mutated in many primary and metastatic human cancers. It 
has lipid and protein phosphatase activities, which are both required to inhibit 
cellular invasion and mediate most of its largest effects on gene expression. 
PTEN can antagonize the PI3K/AKT pathway by dephosphorylating 
phosphatidylinositol 3,4,5 trisphosphate (PIP3) thereby acting as tumour 
suppressor. Most of PTEN’s tumour suppressor activities have been 
attributed to its ability to regulate signalling downstream of AKT. However, 
our recent data in glioma cells have shown that two PTEN mutants, PTEN 
Y138L and PTEN R308C, can regulate AKT phosphorylation and signalling 
downstream but fail to regulate processes such as cell invasion and epithelial 
cell architecture. These findings suggest that in some circumstances the 
regulation not of AKT, but of signalling mechanisms that control invasion 
can correlate with PTEN-mediated tumour suppression. In order to 
understand how PTEN could regulate tumorigenesis, two new transgenic 
knock in mice lines were developed expressing Pten Y138L and Pten R308C 
mutants. The Y138L mutation is embryonic lethal and homozygous embryos 
die at day 9.5 of pregnancy. Interestingly, heterozygous PTEN Y138L mice 
develop tumour as early as 5 months and about half develop tumours before 
18 months of age. R308C heterozygous and homozygous mice are both viable 
instead, but data suggest that the mutation may also be tumorigenic. 
Furthermore, to understand how PTEN WT and PTEN Y138L could regulate 
gene expression, I performed luciferase promoter reporter assays. From these 
first experiments, significant effects of PTEN WT or PTEN Y138L on gene 
expression were not detected. Together, these studies help us understand how 
PTEN suppresses tumour formation in vivo and regulate gene expression. 
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Chapter 1 
1. Introduction 
1.1 General introduction 
Processes that regulate the life of the cells and in particular those that 
influence cell growth and proliferation are properly regulated through highly 
complex and structured signalling systems. Indeed, for normal functioning 
and homeostasis, all multicellular organisms need a fine balance between cell 
growth and cell death. An illustration of this is that defects in the control of 
cell proliferation can lead to hyper-proliferative diseases such as cancer. 
1.1.1 Mechanism of tumorigenesis  
Balance between cell death and proliferation, and balanced regulatory 
exchanges between stromal and epithelial cells are both vital components of 
the dynamic equilibrium of the internal environment of the human body. Loss 
of this balance can lead to cancer: an uncontrolled growth of cells (often 
benign), which can eventually invade other tissues by migrating from their 
original site to proliferate elsewhere (malignant). Tumorigenesis is a process 
of clonal evolution that is initiated from single cells within otherwise 
histologically normal tissue. Cells in normal tissue continually undergo 
mutation; some of those may give the cell a proliferation advantage over the 
other cells in the population. In the carcinogenesis process, cancer cells have 
been shown to accumulate multiple mutations that are believed to drive their 
transformation from normal to tumour cells. Pro-tumorigenic mutations affect 
two classes of genes: oncogenes and tumour suppressor genes (TSGs). 
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Oncogenes are defined as genes in which mutations affect tumour formation 
through gain of function, which can either constitutively activate or lead to an 
increased expression of the oncoproteins, resulting in amplification of their 
functions. The products of oncogenes include transcription factors, chromatin 
re-modellers, growth factors, growth factor receptors, signal transducers, and 
apoptosis regulators Croce (2008). Many of these oncogenes are targets for 
drug development. Small molecule inhibitors of some of these oncoproteins 
have been approved for use and many of them are in clinical trials.  
Mutations in TSGs lead to loss of activity and relieve their inhibition on cell 
growth and proliferation. The first tumour suppressor to be discovered was 
Retinoblastoma (Rb) protein by Alfred Knudson in 1971. He proposed the 
two hit model for loss of function of TSGs which suggested that they undergo 
biallelic inactivation. The inactivation of the first allele could either be germ 
line or somatic. The second mutation is always somatic. The occurrence of 
the second mutation is often detected as an experimental loss of heterozygosis 
(LOH) (Lee & Muller 2010).  
Although supported in some instances by a wealth of data, the two hit model 
however does not apply to all tumour suppressor genes. Only some TSGs are 
truly recessive. Loss of a single copy of some TSGs, also termed as 
haploinsufficiency, may be sufficient to cause a phenotype. Examples of 
haplo-insufficient genes include p53, PTEN, SMAD4 and LKB1 (Berger, 
Knudson et al. 2011), (Berger and Pandolfi 2011).  
In almost all cancers, a single mutation alone is not sufficient for tumour 
progression, except done for cancer types in which very few, or none, 
mutations are identified, i.e. medulloblastoma and some leukemias. Cancer 
cells undergo various genetic and epigenetic changes and acquire biological 
capabilities in a multistep tumour development process which allow them to 
be tumourigenic and ultimately malignant. Robert Weinberg and colleagues 
have classified these acquired capabilities into eight categories and these are 
called as the hallmarks of cancer.  
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One of the early steps in the initiation of most tumours is a mutation in 
proteins such as p53 and telomerase, which confers immortality: the ability 
for continuous cell growth and limitless replication. Once the cell is capable 
of uncontrolled proliferation, it needs to rewire its regulatory pathways for 
sustaining the chronic proliferation. This is accomplished by amplification of 
oncogenes involved in growth factor signalling. Examples include receptor 
tyrosine kinases like the EGFR, downstream kinases like PI 3- kinases, AKT, 
mTOR etc. 
In addition, the cell needs to evade growth suppression by loss of function of 
tumour suppressor genes, and resist cell death by mutations of the genes 
responsible for apoptosis. The primary tumour undergoes vascularisation by 
angiogenesis and it can form metastasis of that are initiated by cells escaping 
the primary tumour into the circulation through these blood vessels feeding 
the tumour (Hanahan & Weinberg, 2011). It seems reliable that many and 
perhaps all cancer cells develop also the capability to modify, or reprogram, 
cellular metabolism in order to support neoplastic proliferation and to evade 
immunological destruction, in particular by T and B lymphocytes, 
macrophages, and natural killer cells [T cell subtype]. Currently, there have 
been drugs developed, and some of them are already in clinical trials, which 
interfere with these capabilities of the tumours required for its growth, 
progression and escape from immune system and programmed death (Figure 
1.1).(Hanahan and Weinberg 2011).  
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Figure 1.1| Therapeutic targeting of the Hallmarks of Cancer. Drugs that 
interfere with each of the acquired capabilities necessary for tumour growth 
and progression have been developed and are in clinical trials or in some cases 
approved for clinical use in treating certain forms of human cancer. (Figure 
from Hanahan & Weinberg, 2011) 
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Fearon and Volgestein, using colon carcinogenesis as an example, described 
tumourigenesis, adopting a linear progression model, according to which 
malignant tumours evolve from pre-existing and less aggressive benign 
tumours (Fearon and Vogelstein 1990). This classical model of 
carcinogenesis can be described as a three-step process including initiation, 
promotion and progression. Exposure of cells to endogenous and exogenous 
genotoxic agents (reactive oxygen species (ROS), double strand breaks due 
to UV light, and other reactive metabolites), represents the first step of the 
complicated machinery, resulting in DNA mutations (point mutations, 
deletions, insertions, amplifications, chromosomal translocations) and 
chromosome instability. In particular, changes in genes that themselves 
regulate the repair of DNA damage contribute significantly to tumour 
promotion and progression (Iida, Shimada et al. 2013). Beside genetic 
mutations, non genotoxic agents like diet, obesity and environment are also 
considered as modulators of cancer risk. 
Tumours often possess genetically different clones that arise from initial 
transformed cells through further genetic alterations. This heterogeneity 
contributes to differences in clinical behaviour and responses to treatment of 
tumours of the same diagnostic type. These populations can differ in 
sensitivity to chemotherapy, radiotherapy, and other treatments, making 
clinical management difficult. For these reasons, the initiating steps in the 
development of cancer are of considerable clinical importance and are a 
priority in the development of rational cancer treatment. 
The focus of this Master of Philosophy project is the PI 3-kinase-PTEN 
signalling network whose importance in human cancer has been shown by its 
activation in many, and probably most, tumours. 
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1.2 The PI3-kinases signalling Pathway 
Phosphoinositide 3-kinases (PI 3-kinases) are the most widely studied family 
of PI kinases. As evident from their name, they can phosphorylate the 3rd 
hydroxyl position of the inositol ring of phosphoinositide lipids.  
Phosphatidylinositol and its derivatives form around 2-10% of total cellular 
lipids in eukaryotic cells. They are amphipathic molecules consisting of a 
glycerol backbone, two fatty acid chains and a polar phosphate group 
substituted with an inositol head group. The inositol ring of 
phosphatidylinositol has 5 free hydroxyl groups, 3 of which have been found 
to be phosphorylated, generating a set of lipids that collectively are called 
phosphoinositides (PIs). The phosphoinositides are much less abundant than 
the precursor phosphatidylinositol (Mulgrew-Nesbitt et al, 2006). The 
different phosphoinositides found in cells are PtdIns3P, PtdIns4P, PtdIns5P, 
PtdIns(3,5)P2, PtdIns(4,5)P2, PtdIns(3,4)P2 and PtdIns(3,4,5)P3. 
Phosphoinositides have many functions. They can be metabolised by different 
enzymes such as kinases, phosphatases and lipases to generate secondary 
messengers that play roles in several signalling pathways. Phosphoinositides 
can bind to proteins and affect their localisation (Balla et al, 2009).  
PI 3-kinases have been broadly classified into three classes; Class-I, II and 
III, based on their structure and lipid substrate preference (Domin, Pages et 
al. 1997); (Cantley et al, 2002); (Chalhoub, Zhu et al. 2009); 
(Vanhaesebroeck, Vogt et al. 2010). In particular Class-I PI 3-kinases are the 
most studied of all PI Kinases and use PtdIns(4,5)P2 as a cellular substrate to 
give PtdIns(3,4,5)P3 and are activated  by receptor tyrosine kinases, cytokine 
receptors and also some G Protein Coupled Receptors (GPCR) (Guillermet-
Guibert et al, 2008). PtdIns(3,4,5)P3 then mediates its effects on cellular 
behaviour through proteins that are able to selectively bind to the lipid. The 
best recognised PtdIns(3,4,5)P3 effector proteins bind to the lipid through 
pleckstrin homology (PH) domains, and include Ser/Thr kinases such as AKT 
and PDK1, Tyrosine kinases, adaptor proteins and regulators (GAPs and 
GEFs) of small GTPases of the Rac and ARF families. Binding of these 
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proteins to the PtdIns(3,4,5)P3 in the membrane triggers a cascade of 
downstream signalling events (Engelman, Luo et al. 2006).  
1.2.1 The PI-3Kinase/AKT pathway 
One of the most studied effectors of the Class-I PI 3-kinases is AKT. It is a 
Ser/Thr protein kinase which was discovered based on sequence homology to 
v-AKT, the transforming oncogene of the AKT 8 retrovirus Staal (1987). 
Mammalian cells express three different isoforms of AKT: AKT 1, AKT 2 
and AKT 3. The AKT kinases have a PH domain which can bind to 3-
phosphoinositides such as PtdIns(3,4,5)P3 and PtdIns(3,4)P2. The mechanism 
of upstream activation of all three isoforms appears the same. However they 
may have different downstream effectors. AKT 1 and AKT 2 are more widely 
expressed than AKT 3. 
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Figure 1.2| The PI3K/AKT and related pathways. The PI3K/AKT and 
related pathways are important in internalizing the effects of external growth 
factors and of membrane tyrosine kinases. Activation of membrane kinases 
including epidermal growth factor receptor (EGFR) by external growth 
factors initiates receptor dimerization and subsequent events to activate these 
intracellular pathways. AKT is activated downstream of PI3K and has 
multiple targets. It is involved in regulation of growth, apoptosis, glucose 
metabolism, cell cycle and DNA repair (Hennessy 2005). 
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The AKT proteins are approximately 65kDa proteins. They have a canonical 
N-terminal PH domain, which facilitates binding to phosphoinositides, a 
central kinase domain and a C-terminal hydrophobic motif (HM). The kinase 
domain and HM of AKT bears high sequence homology to other members of 
the AGC kinases. 
PtdIns(3,4,5)P3 binding to the PH domain of AKT brings about a 
conformational change in AKT exposing two critical phosphorylation sites. 
Thr-308, present in the activation loop of the kinase domain is phosphorylated 
by PDK1 and Ser-473 in a hydrophobic motif is phosphorylated by the 
mTORC2 (mTOR-Rictor) complex. Phosphorylation at these sites stably 
activates the kinase activity of AKT which can then phosphorylate 
downstream effector proteins in multiple locations and control processes such 
as protein synthesis, survival, proliferation, glucose metabolism etc. The 
minimal substrate phosphorylation motif for AKT has been identified as R-
X-R-X-X-S/T- β, where S/T represents the serine or threonine residue that 
becomes phosphorylated and β represents a large hydrophobic residue 
(Alessi, Caudwell et al. 1996). A large number of candidate are reported, 
however not all have been characterised in detail. It has been demonstrated 
that AKT has a critical role in promoting cell survival, and it fulfils this 
function by blocking directly the expression of proapoptotic Bcl-2 homology 
domain 3 (BH3)-only proteins such as BAD, which usually inactivates pro-
survival Bcl-2 family members, or through effects on transcription factors 
such as FOXO and p53. Indeed, FOXO (1, 3a, and 4), phosphorylated by 
AKT, is exported from the nucleus by 14-3-3 proteins-binding with block of 
FOXO-mediated transcription of target genes (including FasL and Bim), 
which promote apoptosis, cell-cycle arrest, and control many metabolic 
processes (Brunet, Bonni et al. 1999); Dijkers, Birkenkamp et al. (2002). In 
contrast, phosphorylation of E3 ubiquitin ligase MDM2 by AKT promotes its 
translocation to the nucleus where it triggers p53 degradation and thus cell 
survival (Mayo, Dixon et al. 2002). AKT can inhibit apoptosis through effects 
on several other targets such as inhibition of GSK3 and JNK/p38 apoptotic 
signals, or activation of NFKB 45 survival signalling (Cross, Alessi et al. 
1995); (Kim, Zhou et al. 2006); (Maurer, Charvet et al. 2006); (Ozes, (Mayo 
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et al. 1999), however their functions are less clear. An important downstream 
substrate is the mammalian target of rapamycin kinase mTOR, a critical 
regulator of cell growth. mTOR complex 1 (mTORC1) or its downstream 
substrates, S6K1 and 4E-BP1(eukaryotic initiation factor 4E (eIF4E)-binding 
protein 1), is phosphorylated and activated by AKT. AKT can regulate 
mTORC1 also through inhibition of the tumour suppressor TSC2 (tuberous 
sclerosis complex 2), a negative regulator of the complex. In addition, 
phosphorylation of TSC1/2 complex, inhibitor of Ras-related small G protein 
Rheb, relieves its inhibition of Rheb activity, leading to activation of the 
rapamycin-sensitive mTOR complex (mTORC1) (Gao and Pan 2001); 
(Potter, Pedraza et al. 2002); (Sekulic, Hudson et al. 2000); (Tapon, Ito et al. 
2001). Activated AKT modulates also the function of multiple downstream 
targets involved in the regulation of cell proliferation, glycogen metabolism 
and protein synthesis. The AKT kinases are strongly activated by insulin and 
of the three AKT isoforms, AKT 2 is most strongly associated with glucose 
homeostasis. Initial studies using knock-out mice showed that AKT 2 null 
mice were glucose intolerant and insulin resistant which led to diabetes and 
pancreatic β cell failure. This was due to defective glucose uptake on insulin 
stimulation by the muscle and adipose tissue. AKT 1 and AKT 3 null mice 
had normal glucose metabolism. The mechanism for this was reported to be 
AKT 2 dependent regulation of the Glut4 glucose transport protein. On 
insulin stimulation, Glut4 containing intracellular vesicles are rapidly 
translocated to the plasma membrane where the vesicles fuse with the 
membrane and insert Glut4 in cell the membrane. Once at the membrane, 
Glut4 allows glucose uptake. Translocation of Glut4 requires activity of Rab 
proteins. AKT plays a major role in this process by phosphorylating and 
inhibiting the GAPs for the Rab proteins. This releases the GAP inhibition of 
the respective Rab proteins and this activates them facilitating Glut4 
translocation. One such GAP regulated by AKT is the AS160 (or TBC1D4) 
protein (Miinea, Sano et al. 2005). AKT can phosphorylate AS160 at 5 
residues (Ser- 318, Ser-570, Ser-588, Thr-642 and Thr-571) in response to 
insulin stimulation, and inhibit its GAP activity.  GSK3 enzymes are known 
to regulate Glycogen synthase, which converts glucose to glycogen. AKT can 
phosphorylate GSK3α and β at the Serine 9 and 21 respectively and inhibit 
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the kinase activity of GSK3 and thus inhibits glycogen synthesis. Inhibition 
of GSK3B is also known to promote sterol regulatory element binding 
proteins, which can induce transcription of genes required for cholesterol and 
fatty acid biosynthesis. Almost 100 substrates have been proposed for GSK3 
that suggests that it can regulate multiple cellular processes (Sutherland, 
2011) (Figure 1.2). 
The importance of this pathway is assessed also by studies conducted in other 
organisms, as yeast, Caenorhabditis elegans and Drosophila. Although class 
I phosphatidylinositol 3-kinases (PI3Ks) have not been found in yeast, there 
is some evidence of pathway conservation. Homologues of other members of 
the PI3K pathway have been described, including two PDK homologues, 
named Pkh1 and Pkh2 (Pkb-activating kinase homologues 1 and 2), which 
are essential for viability and activate human AKT1 in vitro112, and two Tor 
proteins that regulate biosynthesis.  In C. elegans, the PI3K (or Age1) 
signalling pathway regulates adult longevity and dauer diapause, a larval 
developmental stage that is induced by unfavourable environmental 
conditions. The C. elegans insulin receptor Daf2 lies upstream of Age1 and 
signals through Akt1 and Akt2 in a process that also requires the activity of 
Pdk1. The homology of the pathway extends to downstream targets of Akt, 
such as the forkhead transcription factor Daf16 and to negative regulators, 
such as Daf18, the C. elegans PTEN homologue. Drosophila homologues 
exist for all characterized members of the PI3K pathway, from insulin-like 
peptides to downstream effectors of Akt. Genetic studies have implicated 
PI3K signalling in cell growth and proliferation. The fly phenotype of loss-
of-function mutants in the pathway is a decrease in organ and body size owing 
to changes in cell size and number. Conversely, mutations in the negative 
regulator Pten cause an increase in cell size and cell proliferation (Vivanco 
and Sawyers 2002).  
The Class I PI 3-kinase/ AKT signalling system is one of the most important 
that mammalian cells use to control cell growth and proliferation. Indeed 
aberrations in this pathway have implications in metabolic and hyper-
proliferative disorders such as diabetes and cancer. Specifically, functions of 
the many members of the PI 3-kinase signalling pathway are found to be 
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altered in many types of cancers. There is frequent amplification of the 
function of proteins such as RTKs, PI 3-kinase and AKT and loss of function 
of negative regulators, such as PTEN and INPP4B in cancer. Thus PI 3-kinase 
pathway effector proteins are a common target for cancer therapy. Various 
small molecule inhibitors for RTKs, PI 3-kinases, AKT and downstream 
effectors such as mTOR are being used as drugs for treating cancers with 
amplified PI 3-kinase signalling (McNamara and Degterev 2011), 
(Vanhaesebroeck, Guillermet-Guibert et al. 2010); (Wong, Engelman et al. 
2010); (Zhao and Vogt 2008).  
There are several inhibitory component of the PI3K pathway (phosphatases, 
E3 ligases etc), but it appear the most frequently changed in cancer is the PIP3 
phosphatase PTEN. The PI 3-Kinase / AKT pathway is mainly antagonized 
by PTEN that is a soluble, largely cytosolic protein that removes PIP3 by 
acting as an interfacial phosphatase at the cell membrane.   
1.3 PTEN 
Homozygous deletion of regions of human chromosome 10q23 is a common 
event found in many human cancers especially glioblastoma multiforme. 
Mapping of these deletions led to the discovery of PTEN as a putative tumour 
suppressor (Li, Yen et al. 1997); (Steck, Pershouse et al. 1997). Since then, 
PTEN mutations have been reported in a multitude of human cancers (Ali, 
Schriml et al. 1999); (Bonneau and Longy 2000). Mouse models have also 
been used to confirm the effects of PTEN loss and mutation on tumour 
development in many tissues. Biochemical studies have explained the 
functions of PTEN. All of these have improved our understanding of the 
tumour suppressor functions of PTEN and are discussed below in detail. 
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1.3.1 PTEN structure 
The predominant form of human PTEN is a 403 amino acid cytosolic protein. 
It can be structurally divided mainly into an N-terminal phosphatase domain 
and a C-terminal C2 domain. It also has a short 7 amino acid N-terminal 
sequence, also called PtdIns(4,5)P2 binding motif (PBM), which, along with 
the extreme N-terminus of the phosphatase domain is required for binding to 
the membrane lipid PtdIns(4,5)P2 (Walker, Leslie et al. 2004). Finally, there 
is a C-terminal tail with limited structure consisting of several 
phosphorylation sites.  At its extreme C-terminus PTEN has an ITKV motif 
which is responsible for interaction with PDZ domains and is called the PDZ 
binding motif (PDZBM). A crystal structure of PTEN was reported in 1999 
(Lee, Yang et al. 1999). (Figure 1.3) PTEN consists of three unstructured 
regions or loops which are sensitive to proteolytic digestion and were not 
included in the crystal structure. These include the N-terminal PBM (residues 
1-7), C terminal tail (residues 354- 403, 50 amino acids) and a 24 amino acid 
internal loop in the C2 domain (residues 286-309, named the DLoop by 
Spinelli et al, unpublished data). 
Although PTEN belongs to the PTP family of Dual Specifity Phosphatases 
(DSPs), that dephosphorylate both phospho-tyrosine and phospho-serine/ 
threonine substrates. It contains the signature catalytic motif HCXXGXXR 
of the family (also called the P loop) and it bears very little sequence 
homology with most other members of this family outside this catalytic motif.  
The phosphatase domain consists of five central β- strands flanked by two α- 
helices on one side and five α-helices on the other. The catalytic pocket of 
PTEN consists of the P-loop and WPD loop residues, which play a role in 
catalysis, substrate recognition and conformation of the catalytic pocket.  
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Figure 1.3| a. The domain structure of phosphatase and tensin homologue 
(PTEN). PTEN is a 403 amino acid protein that is composed of five functional 
domains: a phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2)-binding 
domain (PBD), a phosphatase domain, a C2 domain, a carboxy-terminal tail 
and a PDZ-binding domain. b. Overview of the PTEN protein structure. The 
structure of the PTEN phosphatase domain (dark blue) consists of a central 
five-stranded β-sheet that packs with two α-helices on one side and four on 
the other. The C-terminal 170 amino acids of PTEN fold into a β-sandwich, 
containing two antiparallel β-sheets with two short α-helices intervening 
between the strands (orange). c. Active sites of PTEN. The larger width of 
and the positive charge in the PTEN pocket are important for the 
accommodation of phosphoinositide substrates, as demonstrated here by 
Ins(1,3,4,5)P4. (Figure adapted from Song 2012) 
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1.3.2 PTEN as lipid and protein phosphatase 
PTEN has the signature catalytic motif of the PTP family of dual specificity 
phosphatases. This sub-family get their name from their ability, shared by 
PTEN, to dephosphorylate both phospho-tyrosine and phospho-serine/ 
threonine substrates.  
When first cloned, PTEN was classified as a protein phosphatase since it 
contained the signature motif HCXXGXXRS/T found in protein tyrosine 
phosphatase (PTPs) and dual-specificity phosphatase (DSPs) (Li, Yen et al. 
1997); (Myers and Tonks 1997); (Steck, Pershouse et al. 1997); (Tonks and 
Neel 1996); (Yuvaniyama, Denu et al. 1996). Within this motif, the conserved 
active site cysteine 124, located at the base of the catalytic pocket, is required 
for the catalytic activity of PTEN, as its sulfhydryl group functions as a 
nucleophile that attacks the phosphorous atom of its substrate with the 
formation of a thiophosphate-enzyme intermediate (Myers and Tonks 1997); 
(Zhou, Tarmin et al. 1994). Indeed, mutation of cysteine 124 to serine in 
PTEN resulted in a complete loss of its phosphatase activity and in the ability 
of PTEN to control cellular growth in PTEN-deficient tumour cell  (Furnari, 
Lin et al. 1997), (Furnari, Huang et al. 1998); (Li and Sun 1997). PTEN 
exhibits a robust phosphatase activity against the highly acidic and artificial 
random copolymer of glutamate and tyrosine, (polyGlu4,Tyr1). Several 
studies have observed changes in PtdIns(3,4,5)P3 levels when PTEN was 
overexpressed in different cell lines including HEK293T cells and glioma 
cells, with alteration of the signalling downstream of PI3-Kinase, whereas 
PTEN C124S, unable to dephosphorylate protein substrates, was also unable 
to dephosphorylate PtdIns(3,4,5)P3 (Maehama and Dixon 1998); (Myers et 
al., 1998). Characterisation of the lipid phosphatase activity of PTEN 
demonstrated that it can hydrolyse PtdIns(3)P, PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3, showing high specificity for the latter even when compared 
with its water-soluble head group, Ins(1,3,4,5)P4 (McConnachie, Pass et al. 
2003); (Myers, Pass et al. 1998). Taken together, these data confirmed 
PtdIns(3,4,5)P3 as a physiological lipid substrate for PTEN. 
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Recently, it has been demonstrated that minimal part of the total amount of 
PTEN in the cell exists in a dimeric conformation. Dimeric PTEN complexes 
are more active than PTEN monomer in dephosphorylating PIP3 and 
regulating PI3K signalling. In particular, Papa et al showed that while 
disrupting PTEN activity in cis, PTEN C124S and PTEN G129E inhibit the 
WT protein function in trans in a dominant- negative manner as a result of 
heterodimerization. In turn, this reduced Pten lipid-phosphatase activity leads 
to Akt hyperactivation and increased tumourigenesis in the mouse. Moreover, 
it has previously been published that phosphorylation of the PTEN tail is 
known to produce an inactive form of the enzyme in a closed conformation 
(Leslie and Foti 2011). In agreement, Papa et al. provide evidence that 
dephosphorylation of the PTEN-tail, while favouring a more open 
conformation, also allows subsequent dimerization and, possibly, 
oligomerization, in view of the multiple interfaces found to mediate the 
PTEN-PTEN interaction (Papa et al. 2014). 
In contrast to its lipid phosphatase activity, PTEN has a weaker activity was 
detected when a PTEN against the common protein tyrosine phosphatase 
substrates, and complete ablation of PTEN catalytic activity was observed 
when the mutant PTEN C124S was used. PTEN favours acidic peptides but 
will not dephosphorylate all acidic phospho peptides which shows that even 
PTEN’s protein phosphatase activity has some degree of substrate specificity 
(Myers and Tonks 1997). Various studies have suggested that PTEN’s protein 
phosphatase activity has important biological consequences. While some of 
these effects have been proposed to require PTEN’s ability to 
dephosphorylate heterologous protein substrates, the others are indirect 
consequences of PTEN’s protein phosphatase activity. These have been 
discussed below.  The importance of PTEN’s protein phosphatase activity 
over its lipid phosphatase activity in these processes has been implicated in 
studies using the PTEN mutant G129E. This PTEN mutation was found in 
two Cowden disease families (Liaw, Marsh et al. 1997). The Glycine 129 
residue is present at the bottom of the catalytic pocket of PTEN (Lee, Yang 
et al. 1999). Mutation of this residue to glutamic acid reduces the size of the 
pocket. This selectively impairs the ability of the mutant PTEN enzyme to 
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metabolise the lipid substrate PtdIns(3,4,5)P3 and its soluble head group 
Inositol (1,3,4,5)-tetrakis phosphate (IP4). However, this mutant retains the 
ability to metabolise the peptide substrate PolyGluTyr(P) (Furnari, Huang et 
al. 1998); (Myers and Tonks 1997), (Myers, Pass et al. 1998). Its activity 
against phosphorylated serine/threonine substrates has not been tested. The 
low protein phosphatase activity measured for PTEN compared to other 
PTPs, suggested that PTEN might be active against non-protein substrates. 
Tamura and colleagues showed that PTEN inhibited fibroblast migration, and 
they correlated this effect to its association with the focal adhesion kinase 
(FAK), which was shown to be dephosphorylated by PTEN. However, later 
findings reported that FAK was not dephosphorylated when a protein 
phosphatase active, Cowden-associated mutation, PTEN G129E, was used. 
Therefore, this implied the presence of other substrates for PTEN (Myers and 
Tonks 1997); (Tamura, Tamura et al. 1998). Therefore, the finding of PTEN 
as a PtdIns(3,4,5)P3 phosphatase implied that deletion or mutations of PTEN 
led to the activation of PI3-kinase pathway. several substrates have been 
proposed for PTEN such as FAK, Shc, IRS-1, Fyn, p85β, PDGFR, β-catenin, 
5 H2TC, Par3, CREB, Cyclin D1 and PTEN itself. (Tamura et al. 1998) (Gu, 
Zhang et al. 2011), (Dey, Crosswell et al. (2008); (He, Ingram et al. 2010); 
(Ramachandran, Barria et al. 2009); Gu, Zhang et al. 2011);Vogelmann, 
Nguyen-Tat et al. 2005), (Tibarewal, Zilidis et al. 2012). In particular PTEN 
appears to dephosphorylate itself at Threonine 366 being able to autoregulate 
its lipid phosphatase activity, in fact mutation of this site makes lipid 
phosphatase activity sufficient for PTEN to inhibit invasion (Tibarewal, 
Zilidis et al. 2012) and control epithelial morphology (Berglund et al, 2013). 
The role of PTEN’s protein phosphatase activity has also been implicated in 
inhibition of cell migration and epithelial to mesenchymal transition (EMT) 
(Leslie, Yang et al. 2007); (Tamura et al. 1998). A summarized illustration of 
PTEN as lipid and protein phosphatase is shown in Figure 1.4 
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Figure 1.4| Reported sites of action of PTEN. Extracellular interactions 
trigger signalling from integrins and growth factor receptors. The major 
function of PTEN is the downregulation of the PI3-Kinase product 
PtdIns(3,4,5)P3, which regulates Akt and complex downstream pathways 
affecting cell growth, survival and migration. In addition, PTEN has weak 
protein tyrosine phosphatase activity, which may target focal adhesion kinase 
(FAK) and Shc, and thereby modulate other pathways. The phosphatase 
domain of PTEN (red) may dephosphorylate and downregulate (red lines) 
substrate molecules (Figure from Yamada and Araki (2001). 
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1.3.3 Mutational spectra of PTEN 
PTEN is constitutively expressed in normal cells but under pathological 
conditions, PTEN levels can be dramatically reduced, indeed it is been found 
mutated in many primary and metastatic human cancers. Homozygous 
deletion of regions of human chromosome 10q23 is also a common event 
found in human tumours especially glioblastoma multiforme (Ali, Schriml et 
al. 1999); (Bonneau and Longy 2000). 
PTEN mutations can either be germline or somatic. Germline mutations of 
PTEN can lead to the PTEN Hamartoma syndrome (PHTS) and are also 
linked to autism, whereas somatic mutations occur in many sporadic cancers. 
PHTS are characterised by formation of histologically distinct subtype of 
benign tumours called hamartomas. PHTS can be further classified into 
Cowden syndrome, Bannayan Riley Ruvalcaba syndrome, Lhermitte Duclos 
disease and Proteus syndrome. The most common of these is Cowden 
Syndrome. It is characterised by hamartomas of skin, breast, thyroid, 
endometrium, gastrointestinal tract and central nervous system, and a 
predisposition to malignancies of breast (25-50% of affected women) and 
thyroid (3-10% of all affected patients). Table 1.9 shows the frequency of 
PTEN mutations and clinical manifestations in the above mentioned 
syndromes. PTEN germline mutations also lead to Autism spectrum disorder 
(ASD) with macrocephaly. Germline mutations of PTEN have also been 
found in patients diagnosed as having GI tract hamartoma syndromes such as 
Peutz Jeghers Syndrome and Juvenile Polyposis Syndrome (Ali, Schriml et 
al. 1999); (Blumenthal and Dennis 2008). 
Homozygous mutations and loss of heterozygosity of PTEN are common 
features of many cancers as shown in Table 1.1. Somatic loss of PTEN 
function through mutation, deletion and promoter methylation is a common 
event in many human cancers. The COSMIC database 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/) provides a comprehensive 
list of somatic mutations of PTEN found in human cancers (Chalhoub and 
Baker 2009); (Wong, Engelman et al. 2010). A histogram of the frequency of 
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mutations for individual amino acids of PTEN is shown in Figure 1.5. 
Highlighted in this figure are the mutational hotspots in PTEN. 
 
Table 1.1| Summary of evidence for PTEN and Pten alteration in specific 
cancers, by tissue (Table adapted from Hollander, Blumenthal et al. 2011) 
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Figure 1.5| Somatic mutations of PTEN found in human cancers. The 
histogram shows the frequency of single amino acid mutations of PTEN from 
the COSMIC database (http://www.sanger.ac.uk/genetics/CGP/cosmic/). The 
amino acids are shown along the Xaxis and the number of mutations found 
is shown on the Yaxis. The mutational hotspots have been indicated in the 
figure. It is noteworthy that all these amino acids are arginines and have the 
CGN codon (R130CGA, 173CGC, R233CGA and R335CGA). Of the 
20 arginines in PTEN, 6 have the CGN codon (above mentioned, R142 and 
R308) and the remaining have AGN codons. 
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1.3.4 PTEN mouse models 
Mouse models of human cancer have played a vital role in understanding 
tumourigenesis and answering experimental questions that other systems 
cannot address. Advances continue to be made that allow better 
understanding of the mechanisms of tumour development, and therefore the 
identification of better therapeutic and diagnostic strategies. Many research 
groups have used mice models to reconstruct in vivo the effects of PTEN loss 
and mutations on tumour development and cancer progression.  
To examine the role of PTEN in ontogenesis and tumour suppression, the 
groups of Pandolfi, Mak, Parsons and Wu each developed transgenic mice 
characterized by the disruption of mouse PTEN expression on different 
genetic background (Table 1.2) using homologous recombination in mouse 
ES cells they have generated mutations that result in the complete 
recombination to delete Pten. In all models, Pten inactivation resulted in early 
embryonic lethality, reported at different stages of the pregnancy (E7.5, E9.5, 
E6.5 and E9.5 respectively). Indeed Pten –/– ES cells formed aberrant 
embryoid bodies and displayed an altered ability to differentiate into 
endodermal, ectodermal and mesodermal derivatives. Pten +/– mice and 
chimeric mice derived from Pten +/– ES cells showed hyperplastic-dysplastic 
changes in the prostate, skin and colon, which are characteristic of formation 
of benign tumours Di Cristofano, Pesce et al. (1998). Each group observed 
tumours in heterozygous mice, the onset and spectrum of tumour formation 
depending significantly on the genetic background but less on the type of 
mutation generated (Freeman, Lesche et al. 2006). 
On the 129/BALB/c genetic background, the onset and spectrum of tumour 
development of Pten-/+ mice were significantly different from the previous 
reports, in almost all of which were done on the 129/C57 or 129/CD1 
background (Table 1.2).  The onset of tumour formation on the BALB/c 
background is significantly delayed versus other findings, which report 
spontaneous development of malignant tumours in <3.5 months. The 
spectrum of tumours is also quite different (Table 1.2). Previously reported 
23 
 
tumour incidences on the 129/C57 or 129/CD1 backgrounds were biased 
towards tissues and organs such as lymphoid, endometrial, adrenal, thyroid, 
gastrointestinal, and mammary glands. In the 129/BALB/c background, aged 
animals, ranging from 7 to 14 months, the incidences of lymphoid and 
endometrial hyperplasia or neoplasia were rather low (25% and 9%, 
respectively). These findings suggest that PTEN plays a critical role in cancer 
development, and genetic background may influence the onset, the spectrum, 
and the progression of tumourigenesis caused by Pten mutation (Di 
Cristofano, Pesce et al. 1998); (Podsypanina, Ellenson et al. 1999); (Suzuki, 
Yamaguchi et al. 2001); (Freeman, Lesche et al. 2006); (Wang, Karikomi et 
al. 2010). 
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Table 1.2| A comparison between Pten heterozygous tumour models (Di Cristofano, Pesce et al. 1998); (Podsypanina, Ellenson 
et al. 1999); (Suzuki, Yamaguchi et al. 2001); Freeman, (Lesche et al. 2006); (Wang, Karikomi et al. 2010)). 
25 
 
In addition, Pten inactivation enhanced the ability of ES cells to generate 
tumours in nude and syngeneic mice, due to increased anchorage-independent 
growth and aberrant differentiation. (Di Cristofano, Pesce et al. 1998); 
(Podsypanina, Ellenson et al. 1999); (Suzuki, Yamaguchi et al. 2001); 
(Freeman, Lesche et al. 2006); (Wang, Karikomi et al. 2010) (Stambolic, Tsao 
et al. 2000). These data suggested that Pten is a tumour suppressor essential 
for embryonic development and Pten haploinsufficiency plays a causal role 
in tumourigenesis and tumour pathogenesis. Moreover the dose of Pten also 
affects cancer progression. A hypomorphic Pten mouse mutant series has 
been generated by homologous recombination with decreasing Pten activity 
and this study has shown that the extent of Pten inactivation dictates in a dose-
dependent way prostate cancer progression, its incidence, latency, and 
biology affecting key downstream targets such as Akt, p27Kip1, mTOR, and 
FOXO3. In particular Pten hypomorphic mice (Pten hy/+), expressing 80% 
normal levels of Pten, develop a spectrum of tumours, with breast tumours 
occurring at the highest penetrance suggesting that subtle reductions in the 
dose of Pten expression predispose to tumourigenesis in a tissue-specific 
manner  (Trotman, Niki et al. 2003); (Alimonti, Carracedo et al. 2010).  
To further analyse the consequences of Pten loss in other organs, several 
tissue specific models of Pten deletion have been developed using a 
conditional gene-targeting approach. They mimic the effect of the loss of Pten 
observed in human tissues, such as brain, prostate, and breast, although not 
all lead to tumours. 
The first three mouse models of tissue-specific inactivation of Pten were 
generated in 2001 (Backman, Stambolic et al. 2001); ( Groszer, Erickson et 
al. 2001); (Kwon, Zhu et al. 2001) with the brain chosen as a target organ. 
PTEN is very highly frequently mutated in glioblastoma (30%, with 70% 
showing gene copy number reduction), the most aggressive primary brain 
tumour in humans (Knobbe, Merlo et al. 2002) and (2) syndromes associated 
with germline mutation of PTEN are characterized by neurological 
abnormalities. Two of these mouse models generated faithfully recapitulated 
the features of Lhermitte-Duclos Disease (LDD). In these mice, Pten is 
deleted late in the development of granule neurons of the cerebellum and 
26 
 
results in a cell autonomous loss of size regulation (Backman, Stambolic et 
al. 2001); (Kwon, Zhu et al. 2001). Indeed, several studies have established 
that deletion of Pten in different neuronal types during development results 
in marked defects in migration and patterning in brain (Backman, Stambolic 
et al. 2001); (Kwon, Zhu et al. 2001); (Marino, Krimpenfort et al. 2002); 
(Yue, Groszer et al. 2005). Although PTEN is frequently inactivated in 
malignant human brain tumours, PHTS is not associated with an increased 
incidence of brain tumours, and mice with heterozygous loss of Pten fail to 
develop brain tumours. Brain tumours are also not observed in conditional 
knockouts targeting Pten deletion in the brain (Backman, Stambolic et al. 
2001); (Kwon, Zhu et al. 2001); (Marino, Krimpenfort et al. (2002); (Groszer, 
Erickson et al. 2001); indicating that cooperating mutations in other genes are 
required for the neoplastic process as demonstrated in further studies 
combining the loss of PTEN with simultaneous loss of p53. 
Prostate cancer and glioblastoma cell lines were the first cellular models 
where deletion of the chromosomal region containing PTEN was reported. 
These findings led to the identification of PTEN as a tumour suppressor gene 
(Li, Yen et al. 1997); (Steck, Pershouse et al. 1997). Although human and 
mouse prostates are structurally dissimilar, prostate cancer progression in 
mice and humans is strikingly similar (Trotman, Niki et al. 2003), (Alimonti 
2010 (Alimonti, Carracedo et al. 2010), (Chen, Trotman et al. 2005). Specific 
deletion of Pten in the prostate was achieved by crossing PtenloxP/loxP mice 
with Probasin-Cre (PB-Cre) transgenic mice. Complete loss of Pten results in 
the development of high-grade PIN (HG-PIN) as early as 8 weeks of age, 
together with the concomitant activation of cellular senescence response. HG-
PIN lesions progress then to invasive prostate cancer with complete 
penetrance at 6 months of age. These analyses imply that loss of PTEN is 
critical for prostate cancer initiation (Chen, Trotman et al. 2005). 
A characteristic feature of Cowden disease is the development of benign 
breast hamartomas that are accompanied by a higher risk of breast cancer. 
Although somatic PTEN mutations are detected only in a smaller fraction of 
breast cancer cases (Dahia 2000), LOH at the PTEN locus (10q23) is 
frequently found (40%) (Bose, Wang et al. 1998); The relevance of Pten in 
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breast tumourigenesis was initially highlighted in the mouse model of Pten 
germline heterozygous loss generated by Stambolic et al. Female Pten+/- 
developed mammary tumours at incomplete penetrance, with most of them 
having features of well-differentiated adenocarcinoma (Stambolic, Tsao et al. 
2000). To fully understand the role of Pten in breast tumourigenesis, in 2002 
Li et al. completely deleted Pten expression from mammary epithelium (Li 
and Thompson 2002). Females with mammary-specific Pten deletion develop 
tumours as early as 2 months, which had histological features similar to the 
basal subtypes of human breast tumours. Importantly, it has been recently 
shown that heterozygous inactivation of Pten leads to the formation of basal-
like mammary tumours in mice, and that loss of PTEN expression is 
significantly associated with this subtype of breast cancer in human sporadic 
and BRCA1-associated hereditary breast cancers (Saal, Gruvberger-Saal et 
al. 2008). 
In addition to the heterozygous inactivation of Pten, some groups have 
developed Knock In transgenic mice that express mutants of Pten with the 
intent of generate mice that express stable mutant Pten proteins but 
catalytically inactive. It is known that germline mutations in PTEN cause 
Cowden and Bannayan–Riley–Ruvalcaba (BRR) syndromes, two dominantly 
inherited disorders characterized by mental retardation, multiple hamartomas, 
and variable cancer risk. In vivo models of these pathologies were developed 
generating transgenic knock in mice expressing three sentinel point mutant 
alleles of PTEN identified in patients with Cowden syndrome: the nonsense 
PTEN ∆4–5 and missense PTEN C124R and PTEN G129E. PTEN ∆4–5 and 
missense PTEN C124R are catalytically inactive mutantsinstead, while PTEN 
G129E mutation causes selective loss of activity against PtdIns(3,4,5)P3 it 
keeps the ability to metabolise peptide substrates. All the mutations resulted 
to be early embryonic lethal, mutant homozygous embryos were recovered at 
embryo day (E) 8.5 and E9.5, also with lower than expected frequency. In 
particular the development of the few mutant homozygous embryos at these 
ages was severely compromised, with defects in anterior-posterior patterning, 
failure of axial rotation, and absence of overt tissue differentiation leading to 
resorption by E9.5 The nonsense PTEN ∆4–5 and missense PTEN C124R 
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and PTEN G129E alleles, all lacking lipid phosphatase activity, cause similar 
developmental abnormalities but distinct tumour spectra with varying 
severity and age of onset. This suggested that the variable tumour phenotypes 
observed in patients with Cowden and BRR syndromes can be attributed to 
specific mutations in PTEN that alter protein function through distinct 
mechanisms. 
Moreover, in a more recent publication, cancer-related mutations Pten C124S 
and Pten G129E, induce acceleration of tumourigenesis in above described 
Knock In mice. They specifically act by further lowering Pten activity rather 
than engaging alternative pathways. They inhibit the WT protein function in 
trans in a dominant- negative manner maybe as a result of heterodimerization. 
In turn, this reduced Pten lipid-phosphatase activity leads to Akt 
hyperactivation and increased tumourigenesis in mice. Accordingly, Pten KI 
Pten C124S and Pten G129E mice developed Lhermitte-Duclos disease 
(LDD), as previously reported in mice with total conditional Pten loss, while 
lesions of different histological origins not associated with Pten loss (such as 
sarcomas) were not observed. Thus, this study implies that patients 
harbouring these, or similar loss-of-function missense mutations encoding 
stable inactive proteins, may be more susceptible to malignant cancer and 
may develop it more rapidly than patients expressing reduced levels of PTEN 
or expressing PTEN-destabilizing mutations. PTEN mutational status may be 
utilized to stratify patients who may benefit from earlier and more radical 
therapeutic intervention modalities, potentially leading to improved 
prognoses. Although the possibility cannot be excluded that certain PTEN 
mutations may become competent toward targets not recognized by the wild-
type protein in a ‘‘gain-of-function’’ scenario (Wang, Karikomi et al. 2010), 
these genetic analyses support a model in which the ability of mutant PTEN 
to interfere with WT protein function contributes to exacerbation of tumour 
spectrum compared to Pten heterozygosity (Papa, et al. 2014). 
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1.3.5 PTEN: more than a lipid phosphatase? 
Most of the tumour suppressor activities of PTEN have been attributed to its 
ability to dephosphorylate lipid substrates and thereby regulate signalling 
downstream of AKT. Despite the huge potential of both the phosphatase 
activities of PTEN, understanding mechanisms that are independent from 
AKT inhibition has been an understudied area of research and it seems that 
the studies of PTEN’s ability to metabolise PtdIns(3,4,5)P3 and regulate AKT 
have dominated PTEN research for the last decade. Most of the past studies 
on PTEN’s protein phosphatase activity have relied on the PTEN mutant 
G129E which selectively retains activity against peptide substrates and lacks 
significant PtdIns(3,4,5)P3 phosphatase activity. Using the information from 
the studies on TPTE and TPIP, our group conducted a mutagenic screen to 
identify a PTEN mutant, which selectively lacks activity against peptide 
substrates. TPTE is encoded on chromosome 21 and its expression has only 
been identified in testis (Chen, Rossier et al. 1999). It is 551 amino acids in 
length and unlike PTEN possesses transmembrane domains. Activity assays 
imply that TPTE lacks phosphatase activity against both PtdIns(3,4,5)P3 and 
phosphorylated peptide substrates. This inactivity has been attributed to the 
two amino acid substitutions in the phosphatase active site (+4 and +5 
positions from the catalytic cysteine). Mutations of these two amino acids to 
those found in the PTEN phosphatase active site, reactivates TPTE making it 
capable of metabolizing both lipid and peptide substrates (Davidson, 
Maccario et al. 2010); (Leslie, Yang et al. 2007); (Walker, Downes et al. 
2001). TPIP is encoded on chromosome 13, is 455 amino acids long and like 
TPTE, it also has trans- membrane domains. It has a slightly wider 
distribution compared to TPTE, but is still absent from most tissues. It seems 
to possesses phosphatase activity comparable to PTEN against both 
PtdIns(3,4,5)P3 and PI(4.5)P2 but lacks activity against peptide substrates 
(Davidson, Maccario et al. 2010); (Walker, Downes et al. 2001). The absence 
of PTEN’s protein phosphatase activity in TPIP indicates that PTEN may 
have evolved specifically to retain this activity for specific functions and that 
PTEN’s protein phosphatase activity is not just an accidental by-product of a 
bigger PTP active site. This strengthened the evidence for the significance of 
30 
 
PTEN’s protein phosphatase activity and our group at the University of 
Dundee further investigated this in a physiological context, by performing a 
mutagenic screen informed by these findings to develop a ‘lipid substrate 
only’ mutant of PTENA sequence alignment of the phosphatase and C2 
domains of PTEN, TPTE-reactivated (TPTE-R) and TPIP revealed 11 amino 
acid residues that were conserved in PTEN and TPTE-R but were different in 
TPIP. Single amino acid substitutions of these amino acids were made in 
PTEN with those found in TPIP and the activity of the mutant PTEN proteins 
were assayed against lipid and peptide substrates. At the 138 position, PTEN 
has a Tyrosine residue and the corresponding site in TPIP has a Leucine. 
Within the mutagenic screen, the Tyrosine at the 138 position, essential for 
PTEN protein phosphatase activity, was mutated to Leucine to get the PTEN 
Y138L mutant (Figure 1.6). Phosphatase assays revealed that this mutant 
lacked detectable activity against polyGluTyr(P) but retained activity against 
PtdIns(3,4,5)P3. When expressed in PTEN null cells, PTEN Y138L was 
capable of reducing the levels of cellular PtdIns(3,4,5)P3 and phospho-AKT 
as efficiently as wild type PTEN. Consistent with this were observed effects 
on downstream substrates of AKT such as GSK3 and the ability of PTEN 
Y138L to supress cell proliferation in a colony formation assay which was 
also comparable to the wild type enzyme. However, PTEN Y138L was 
impaired in the regulation of some processes that wild-type PTEN can inhibit. 
These processes include the inhibition of invasion of PTEN null U87MG cells 
and in the EMT of the primitive streak cells of the chick embryo indicating 
the requirement of PTEN’s protein phosphatase activity in these processes 
(Davidson, Maccario et al. 2010). Although the PTEN mutant Y138L was 
identified in a systematic mutagenic screen, it shows the same features of a 
mutant found in two human cancer samples, PTEN Y138C. This mutant is 
characterized by the substitution of the Tyrosine at the 138 position with a 
Cysteine and it was found in a human endometrial carcinoma sample and a 
lung cancer cell line. When expressed at near physiological levels, PTEN 
Y138C, like PTEN wild type and Y138L reduced phospho AKT levels but 
had no effect in suppression of invasion of U87MG cells.  
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Previous studies have shown that another mutant; PTEN R308C shared the 
same features with PTEN Y138L (Figure 1.6). It is able to control cellular 
AKT activity but is unable to control epithelial morphogenesis and cellular 
invasion of U87MG cells. R308C mutation is a missense mutation 
characterized by the substitution of the Arginine at the 308 position with a 
Cysteine located in the so-called Dloop of PTEN. It was found in two 
different human tumour samples, a glioma and a malignant uveal melanoma 
It has both lipid and protein phosphatase activity and it doesn’t appear to 
affect the stability of the PTEN protein in cultured cells. 
A recent work has shown that lipid and protein phosphatase activities are both 
required for PTEN to regulate several biological processes such as cell 
migration, cellular invasion and to mediate most of its largest effects on gene 
expression. Through whole-genome microarray analysis, there were analyzed 
changes of gene expression occurring in U87MG cells grown in 3D cultures 
transduced with the different forms of PTEN grown. The expression of a 
catalytically inactive PTEN mutant had no significant effect on gene 
expression in these cells while Wild-type PTEN altered the expression of a 
large number of transcripts. PTEN G129E, which has only protein 
phosphatase activity, caused modest changes in the abundance of a small 
number of transcripts. PTEN Y138L, which has lipid phosphatase activity 
and can suppress cellular PIP3 levels and AKT activity, shared a large set of 
transcriptional responses with wild-type PTEN, but failed to affect a large 
group of transcripts that were the most highly responsive to the wild-type 
enzyme. Detailed comparisons of the transcriptional responses to wild-type 
and Y138L PTEN showed that almost all probes either responded similarly 
to both enzymes or responded only to wild-type PTEN. Very few probes were 
affected strongly by wild-type and weakly by Y138L, suggesting a 
qualitatively different signalling mechanism mediated only by wild-type 
PTEN, rather than a quantitative difference in the ability of these proteins to 
influence one pathway or set of responses. The comparison of the set of 
transcripts most strongly induced by wild-type PTEN, but not by PTEN 
Y138L, with available gene expression data from human glioblastoma 
samples shows significant overlap between the genes selectively induced by 
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wild-type PTEN and those suppressed in glioblastoma and suggest that this 
transcriptional control pathway may be clinically relevant (Tibarewal, Zilidis 
et al. 2012).  
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Figure 1.6| Schematic structure of PTEN indicating: the PI(4,5)P2 binding site, the Phosphatase domain, the C2 
domain, the D loop and the C-terminal tail. Red arrows show the sites of of Y138L and R308C mutations 
34 
 
Chapter 2 
2. Materials and Methods 
2.1 Animal procedure 
All animal procedures were conducted following Home office guidelines under 
Project License authorisation (PPL 60/3989). Transgenic mice were initially 
generated by Taconic Artemis (Germany) and bred at the University of Dundee 
Transgenic Mouse Facilities. 
2.1.1 Mice genotyping 
Un-purified DNA was released from ear punch biopsys of mice generally taken 
at weaning adding 20 µl of MicroLysis Plus. The samples were placed in a 
Thermo Cycler used following the lysis program (Step 1: 65°C for 15 mins, 
Step 2: 96°C for 2 mins, Step 3: 65°C for 4 mins , Step 4: 96°C for 1 mins, 
Step 5: 65°C for 1 mins, Step 6: 96°C for 30 secs, Step 7: 20°C hold).  The 
DNA was amplified in PCR using the KAPA Biosystems 2G Fast HS PCR 
KIT according to manufacturer’s instructions, to detect the Neomicin 
resistance cassette inserted in the PTEN mouse gene. The products of the 
PCRs were detected with gel electrophoresis. Primers used in PCR are listed 
in Table 2.1. 
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Primers 
PTEN 5’ 
Hypomorph 
5'-TGTTTTTGACCAATTAAAGTAGGCTGTG-
3' 
PTEN 3’ 
Hypomorph 
5'-AAAAGTTCCCCTGCTGATGATTTGT-3' 
PTEN FLOX 
common   
5'-TTGCACAGTATCCTTTTGAAG-3' 
PTEN FLOX wt 5'-GTCTCTGGTCCTTACTTCC-3' 
PTEN FLOX Neo 5'-ACGAGACTAGTGAGACGTGC-3' 
PTEN 5’ Y138L 5'-ATGGAAAGGAGTAAATGGATGG-3' 
PTEN 3’ Y138L 5'-GGAGTAAAAGCAGGAGAATTGG-3' 
PTEN 5’ R308C 5'-CACTGTAAGGTAAGTCCTATGAAGC-3' 
PTEN 3’ R308C 5'-GGAGTAAAAGCAGGAGAATTGG-3' 
Table 2.1| Primers for genotyping 
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2.1.2 Embryonic lethality determination 
Pregnant female mice were culled at different stage of the pregnancy and the 
embryos were dissected out and snap frozen. Pictures of dissected embryos 
were taken when possible. The genotyping’s PCR protocol was carried out 
on embryos as described above using DNA released from a piece of frozen 
tissue.  
2.1.3 Tissue dissection 
Mice between 38 and 42 days old were culled and the organs were 
immediately dissected and either snap frozen or included in formalin and 
fixed for Immunohistochemistry techniques. Mice identified with tumours 
were immediately culled according to the Home Office animal procedures. 
Tumours and organs were dissected and either snap frozen or incubated in in 
formalin and fixed for Immunohistochemistry/Chloroform. 
2.1.4 RNA extraction and RT-PCR from tissues 
Liver’s tissue sample were reduced in small pieces and homogenised on ice 
using a scalpel. 1ml of Trizol (Life Technologies) was added to the 
homogeniser and the suspension was incubated for 5 minutes at Room 
Temperature.  After the incubation, 100 µl of Chloroform was added to the 
samples mixing for 30 seconds. Samples were left at Room Temperature for 
10 minutes and centrifuged for 15 minutes at 4ºC. For each liver tissue sample 
RNA was isolated using RNeasy Mini Kit (Qiagen) following the 
manufacturer’s protocol. RNA was eluted from columns in nuclease-free 
water. 500 ng of RNA was run on a 2% agarose gel to verify the presence of 
two bands (28S and 18S rRNA) at approximately 4.5 and 1.9 kb, and RNA 
integrity.  
Random hexamer-primed cDNA was synthesised using Sprint RT-random 
hexamer kit (Clontech) following the manufacturer’s protocol. Full length 
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PTEN cDNA was then amplified by PCR with the primer pair listed below 
(Table 2.2). The products were sequenced by Sequencing Service, University 
of Dundee, UK, using internal primers (Table 2.2).  
 
Primers 
PTEN 5’ UTR mouse F 5'-CATGTTGCAGCAATTCACTG-3' 
PTEN 3’ UTR mouse R 5'-GGTATTTTATCCCTCTTGATAAG-3' 
GAPDH mouse F 5’-CAACTCCCACTCTTCCACCTTCG-3’ 
GAPDH mouse R 5’-GTAGGGAGGGCTCAGTGTTGGG-3’ 
Table 2.2| Primers for amplifying cDNA for sequencing 
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2.2 In vitro experiments 
2.2.1 In vitro materials 
Suppliers for main reagents are listed in Table 2.3. 
 
Reagent Suppliers 
1 Kb Plus Ladder Invitrogen 
Agarose Invitrogen 
Albumin Essentially fatty acid free Sigma 
Carbenicillin Sigma Aldrich 
Benzamidine Sigma Aldrich 
Bradford reagent Sigma  
BSA Bovine Serum Albumin Fraction 
V 
Roche 
Chemiluminiscent reagent Millipore 
DTT Sigma 
HRP-linked secondary antibodies Pierce Biotechnology Inc. 
Kanamycin Melford 
Kod Hot Start Polymerase Novagen 
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LDS Sample Buffer Invitrogen 
Luria Broth-LB (powder) Sigma 
MicroLysis Plus Web Scientific 
NuPAGE Novex systems Bis-Tris 
gels 
Invitrogen 
PMSF Sigma 
Primary antibodies See Table x 
Primers MWG 
Promega Dual Luciferase Reagents 
Kit 
Promega 
PVDF membrane Perkin elmer 
QIAshreader columns Qiagen 
Qiaprep Miniprep Kit Qiagen 
Qiaprep Maxiprep Kit Qiagen 
See Blue Plus2 Prestained standard Invitrogen 
Table 2.3| In vitro reagents 
Plasmid expression vectors for PTEN wild-type, PTEN C124S, PTEN 
Y138L, were already in use in the lab. Luciferase promoter reporter plasmids 
used for luciferase assays were kindly provided by other laboratories (Table 
2.3). 
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2.2.2 Preparation of agarose gel  
Agarose gels were prepared by dissolving agarose in TAE buffer (40 mM 
Tris-acetate pH 8.3, 1 mM EDTA) by heating. 10 µl of SYBR safe DNA gel 
stain (Invitrogen) was added and diluited in 100ml of liquid agarose and the 
whole solution agarose poured into gel plates containing well combs. When 
the gel was solidified, it was submerged by adding TAE buffer and the combs 
were removed.  
DNA samples mixed with loading buffer (0.25% (w/v) bromophenol blue, 
0.25% (w/v) xylene cyanol FF, 30% (w/v) glycerol) were loaded into 
individual wells.  
The gel was run at 100 V for 1 hour until the blue tracking dye had migrated 
about 75% of the distance to the end of the gel. The DNA bands were then 
visualised with U.V. light. 1Kb Plus DNA Ladder (Invitrogen) was used as 
marker. 
2.2.3 Preparation of chemically competent 
Escherichia coli cells 
Chemically competent E. coli cells of the strains TOP10 (DNA 
manipulation), and BL21 (protein purification) were prepared using the 
treatment based on the RbCl method. 5 ml of LB medium was inoculated with 
E.coli and left to grow overnight at 37ºC with constant shaking. The overnight 
culture was then diluted into 500 ml of LB medium and left to grow at 37ºC 
for a time required to obtain an OD of 0.5 at 550 nm. The culture was chilled 
on ice for 5 minutes and then harvested by centrifugation at 4000 rpm 
(1600xg) for 10 minutes at 4ºC. The pellet was resuspended in 40 ml of 30 
mM KOAc, 100 mM RbCl, 10 mM CaCl2, 50 mM MnCl2, and 15% glycerol 
(pH 5.8). Cells were harvested as above and resuspended in 7.5 ml of 10 mM 
MOPS, 10 mM RbCl, 75 mM CaCl2, and 15% glycerol (pH 6.5). Aliquots of 
desired volume were prepared and snap frozen in a dry ice/methanol bath and 
stored at -80ºC. 
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2.2.4 Transformation of Escherichia coli with 
plasmids 
Chemically competent E. coli cells of the strains TOP10 (DNA 
manipulation), BL21 (protein purification), prepared as described in Section 
2.2.2, were used for transformations. 100 ng of DNA (the amount can vary 
depending on the transformation efficiency of the vector used) was incubated 
with 10 µl of E. coli competent cells for 20 minutes on ice. The cells were, 
successively, heated at 42ºC for 45 seconds and then placed on ice and left to 
cool for two minutes, before the addition of 250 µl of SOC medium (Super 
Optimal Broth with glucose). The cells were then incubated for 1 hour at 37ºC 
with constant shaking. The bacteria were then plated on selective LB agar 
plates containing the appropriate antibiotic (50 µg/ml ampicillin or 50 µg/ml 
kanamycin) and incubated at 37ºC overnight. 
2.2.5 Purification of plasmid DNA 
Large amount of DNA is generally required for cell transfection. Therefore, 
a small scale (mini-prep) or large scale (maxi-prep) plasmid DNA preparation 
was performed. 4 ml of LB medium containing the appropriate antibiotic was 
inoculated with a single colony picked from the selective LB agar plates, and 
incubated at 37 ºC overnight with constant shaking. After 24 hours, the 
bacterial culture was pelleted at 3250 rpm (1500xg) for 15 minutes and the 
plasmid DNA purified using a 96-well robot (Dundee University service) or 
a Mini-prep kit, purchased from Qiagen (QIAprep Miniprep Kit), according 
to the manufacturer’s instructions. 
For a large scale DNA purification, the starter culture was diluted into 500 ml 
of selective LB medium and incubated at 37 ºC overnight with vigorous 
shaking. Cells were then harvested by centrifugation and the plasmid DNA 
purified using the QIAfilter Plasmid Maxi Kit protocol (Qiagen). 
DNA concentration was determined by measuring the absorbance of a 
dilution of the DNA in water at OD260. The OD260 value was multiplied by 
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the dilution factor and using the relationship that an A260 of 1.0 is 50 µg/ml 
of pure DNA. 
2.3 Proteins analysis 
2.3.1 Preparation of cell and tissues lysates  
The preparation of cell lysate was carried out on ice. The culture medium was 
removed and the cells were washed in ice-cold PBS twice. Lysis buffer 
(25mM Tris‐HCl pH 7.4, 150mM NaCl, 1% NP40, 1mM EGTA, 1mM 
EDTA, 5mM sodium pyrophosphate, 10mM β‐glycerophosphate, 50mM 
sodium fluoride, 0.2mM PMSF, 1mM benzamidine, 1mM sodium 
orthovanadate, 0.1% 2‐mercaptoethanol, 270mM Sucrose) was added and the 
cells were left on ice for 30 minutes prior to being scraped off. Cells were 
collected and centrifuged at 14000 rpm (6000xg) for 20 minutes at 4ºC to 
separate the total soluble protein (supernatant) from the insoluble cellular 
debris (pellet).  
The initial preparation of tissues lysate was carried out on dry ice. Frozen 
tissues were reduced into small pieces using a deep liquid nitrogen scalpel 
and homogenised in cold Lysis Buffer (25mM Tris‐HCl pH 7.4, 150mM 
NaCl, 1% NP‐40, 1mM EGTA, 1mM EDTA, 5mM sodium pyrophosphate, 
10mM b‐glycerophosphate, 50mM sodium fluoride, 0.2mM PMSF, 1mM 
benzamidine, 1mM sodium orthovanadate, 0.1% 2‐mercaptoethanol, 270mM 
Sucrose, 1mM Microcystein) in a homogeniser. Suspensions were 
centrifuged at 14000 rpm (6000xg) for 20 minutes at 4ºC to separate the total 
soluble protein (supernatant) from the cellular debris (pellet).  
The supernatants were then transferred to new tubes and the protein 
concentration estimated as described below. Samples for western blotting 
analysis were then made as described below. 
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2.3.2 Estimation of protein concentration 
The concentration of protein samples was determined using the common 
Bradford method and by reference to absorbance measurements obtained for 
a series of standard BSA (Bovine Serum Albumin) dilutions. 10 µl of sample 
was mixed with 200 µl of Bradford reagent (Sigma) in a 96 well plate. After 
shaking the plate for 30 seconds and 3 minutes of incubation at room 
temperature, the absorbance was measured at 595nm with a plate reader. The 
measurement obtained for the blank was subtracted from all other samples 
measurements (BSA and purified protein) and a standard curve was prepared 
by plotting the standard concentration (µg/ml) vs. measurement of the protein. 
2.3.3 Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
SDS-PAGE was used to separate proteins of interest, by size, shape and 
charge and was performed using NuPAGE Novex system Bis-Tris gels, either 
4-12% gradient or 10% (Invitrogen). The gels were loaded using denaturing 
and reducing conditions following the manufacturer’s instructions and run for 
60 minutes at 200 V in the presence of MOPS running buffer (20X stock: 1 
M MOPS, 1 M Tris base, 69.3 mM SDS, 20.5 mM EDTA free acid). 
2.3.4 Preparation of samples 
The desired amount of purified protein or protein from cell and tissue lysates 
was mixed with 1X LDS sample buffer (Invitrogen) and incubated at 70ºC 
for 10 minutes. 
To run the samples under reducing conditions, β-mercaptoethanol was added 
to the sample buffer. The samples were then mixed and loaded on the gel side 
by side with molecular weight marker SeeBlue Plus2 Prestained standard 
(Invitrogen).  
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2.3.5 Immunological protein detection by Western 
Blotting 
After electrophoresis, proteins were transferred from a gel to a wetted PVDF 
membrane (Perkin Elmer), for 1 hour at 30 V, in the presence of transfer 
buffer (500 mM Bicine, 500 mM Bis-Tris, 20.5 mM EDTA) using a tank wet 
transfer system. Following transfer, the PVDF membrane was dried for 30 
minutes and then blocked with a solution of 5% (w/v) low fat milk protein or 
5% (w/v) BSA made up in TBS-T (200 mM Tris-HCl pH 7.6, 137 mM NaCl, 
1% (v/v) Tween 20). 
The blocked PVDF membrane was washed over 30 minutes with three buffer 
changes of TBS-T, before its incubation at 4ºC with a primary antibody made 
up in 5% (w/v) low fat milk protein or 5% (w/v) BSA (Table 2.4). The time 
of incubation is relative to the antibody used. The primary antibody was 
washed off over 30 minutes with three buffer changes of TBS-T, followed by 
incubation with the appropriate HRP-linked secondary antibodies (Pierce 
Biotechnology Inc) made up in 5% (w/v) low fat milk, for 1 hour at room 
temperature. The unbound antibody was then removed by washing the 
membrane over 30 minutes with three buffer changes of TBS-T. Proteins 
were then detected using chemiluminescence reagents (Millipore). The two 
solutions were mixed and poured on the membrane according to the 
manufacturer’ protocol. The image was acquired directly using a 
chemiluminescence-compatible digital imaging system (CCD camera from 
GE Healthcare), which was also used used for detection.  
2.3.6 Western blot reprobing 
PVDF membrane can be sequentially incubated with different antibodies after 
using the stripping procedure by which the first antibody is removed from the 
blot. 
After washing off the chemiluminescence reagent with multiple TBS-T 
washes, the blot was incubated in a stripping solution (100 mM β-
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mercaptoethanol, 2% (w/v) SDS, 50 mM Tris-HCl pH 6.8) for 30 minutes at 
50ºC with agitation. The blot was then washed for over 30 minutes with three 
buffer changes of TBS-T, followed by the blocking step for the next 
immunodetection. 
Antibody Species Supplier 
Primary antibodies 
AKT Rabbit polyclonal Cell Signalling 
p-AKT (S473) Rabbit polyclonal Cell Signalling 
p-AKT (T308) Rabbit polyclonal Cell Signalling 
FOXO-1 Sheep polyclonal Cell Signalling 
p-FOXO1 Rabbit polyclonal Cell Signalling 
GAPDH 
Mouse 
monoclonal 
Millipore 
p-GSK3 alpha/beta (S21/9) Rabbit polyclonal Cell Signalling 
GSK3-3alpha/beta Rabbit polyclonal Cell Signalling 
mTOR Rabbit polyclonal Cell Signalling 
p-mTOR (Ser2448) Rabbit polyclonal Cell Signalling 
p70 S6 kinase (T389) Rabbit polyclonal Cell Signalling 
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p-p70 S6 kinase (T421/S424) Rabbit polyclonal Cell Signalling 
PRAS40 Rabbit polyclonal Cell Signalling 
p-PRAS40 (p-T246) Rabbit polyclonal Cell Signalling 
PTEN (17A) 
Mouse 
monoclonal 
AbCAM 
PTEN (6H2.1) Rabbit polyclonal Alexis 
Vinculin Rabbit polyclonal Cell Signalling 
Secondary antibodies 
Anti-mouse Rabbit Pierce 
Anti-rabbit Goat Pierce 
Anti-sheep Rabbit Pierce 
Table 2.4| List of antibodies 
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2.4 Cell culture and cell-based assays  
2.4.1 2D culture of cells 
U87MG and DBTRG-05MG glioblastoma cells were originally purchased 
from the ECACC; Human embryonic kidney 293T cells were originally 
provided by Michelle West and Colin Watts (Division of Cell Signalling and 
Immunology, University of Dundee). 
Human embryonic kidney 293T cells were grown in DMEM supplemented 
with 10% fetal bovine serum (FBS) (Sigma) and 1 % L-Glutamine. U87MG 
cells were grown in DMEM supplemented with 10% FBS, 1 % L-Glutamine, 
1% NEAA, 1% Sodium Pyruvate. DBTRG cells were grown in RPMI 
supplemented with 10% FBS, 1% NEAA, 1% Sodium Pyruvate. All the cell 
lines were incubated at 37°C in 5% CO2/95% air. 
For passaging of cells, the monolayer was washed once with warm PBS and 
then incubated with dissociation buffer (Life technologies) at 37°C until the 
cells detached from the surface. The cells were suspended in serum containing 
media to inactivate the buffer and harvested by centrifugation at 150xg for 5 
minutes. The cells were then seeded into flasks at 1:5 in complete medium. 
The media was changed routinely and the cells were split again once they 
were confluent. Cells were counted using a haemocytometer. Normal tissue 
culture plasticware was used for all other cells. For cryopreservation of cells, 
cells were trypsinised, harvested and resuspended in freezing medium 
containing 90% FBS and 10% DMSO at 3x106 cells/ml. 1ml aliquots were 
made in cryovials. The vials were frozen slowly using a controlled rate cell 
freezer before they were stored under liquid nitrogen. 
2.4.2 3D culture of cells 
3D culture of cells was performed using U87MG cells to analyse the 
luciferase activity of the promoter repoter plasmids transfected. U87MG cells 
48 
 
were transfected using TransIT, procedure described in the specific section. 
Growth Factor Reduced Matrigel (BD Biosciences) was defrosted overnight 
on ice in the cold room. 3D cultures were set 18hrs after transfection. 150µl 
of defrosted matrigel was added to pre-chilled 24wells plates placed on ice in 
6 well plates. All matrigel dispensing used pre-chilled pipette tips. The 
matrigel was allowed to solidify at 37°C for 30 minutes. Cells were 
trypsinised and counted. 50,000 cells were plated on top of the solidified 
matrigel and allowed to attach for 30 minutes at 37°C. 100µl of matrigel was 
then poured over the layer of cells to form a sandwich of cells between two 
layers of matrigel. The matrigel was allowed to solidify for 30 minutes at 
37°C. 500µl of complete U87MG media was added to the wells and the cells 
were incubated in a tissue culture incubator for 18hrs and allowed to invade 
through the 3D matrix. After incubation, the cultures were washed once with 
PBS and lysated with Passive Lysis Buffer (Promega). The dual luciferase 
assay was then performed, whom procedure  is described below in details. 
2.4.3 Cell transfection 
DNA was introduced into cells using non-viral methods (transfection). 
Different methods were used depending on the efficiency of transfer and cell 
types.  
2.4.4 Calcium phosphate transfection  
Calcium phosphate transfection method has been used to transfect HEK293T 
cells. 2 hours prior to transfection, cells were split and plated at 30% 
confluence in 10 cm dishes containing 10 ml of medium.  
DNA (10 µg) was added to 61 µl of 2 M calcium chloride (CaCl2), which was 
then made up to a volume of 500 µl. This mix was slowly added to 500 µl of 
2x HEPES buffered solution (HBS, 50 mM HEPES pH 6.95, 280 mM sodium 
chloride, 15 mM disodium hydrogen phosphate). The CaCl2/HBS/DNA 
precipitate was directly added to the cells, covering as much of the plate as 
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possible. After 24 hours of incubation, the cells were changed into fresh 
medium and then incubated for a further 24 hours. 
2.4.5 TransIT-LT1 transfection  
5x105 cells were plated in 24 wells plates containing medium, approximately 
12 hours before transfection. Immediately before transfection, serum-free 
Opti-MEM (31.25 µl) was mixed with warm TransIT-LT1 reagent (3 µl of 
TransIT-LT1: 1 µg of DNA) (Mirus, Madison, WI, USA). The required 
amount of plasmid DNA was gently added to the diluted TransIT-LT1 
reagent. The mix was incubated at room temperature for 15-30 minutes before 
being added dropwise to the cells. The plates were gently agitated to distribute 
the TransIT-LT1 reagent-DNA complexes. After 24 hours of incubation, the 
cells were changed into fresh medium and then incubated for a further 24 
hours. 
2.4.6 Dual-Luciferase assay 
For inhibitor treatments, 1µM GDC0941 (PI3K inhibitor) was added to the 
culture medium 24 hours before performing the assay. To assay luciferase 
activity in cells transfected with luciferase expression vectors, co-transfected 
cells were washed in 1X PBS at Room Temperature and 100 µl (2D culture) 
or 400 µl (3D culture) of Passive Lysis Buffer (Promega) was added to each 
well. After 15 minutes at Room Temperature lightly shaking, 20 µl of the 
lysates was transferred to a 96 wells white plate. The luciferase assay was 
performed using the dual-injector, plate-reading luminometer (Omega Star, 
BMG Labtech) and the Promega Dual Luciferase Reagent Kit accordingly to 
manifacturer’s protocol. The Dual-Luciferase® Reporter (DLR™) Assay 
System provides an efficient means of performing two reporter assays. In the 
DLR™ Assay, the activities of firefly (Photinus pyralis) and Renilla (Renilla 
reniformis or sea pansy) luciferases are measured sequentially from a single 
sample. The firefly luciferase reporter is measured first by adding Luciferase 
Assay Reagent II (LAR II) to generate a luminescent signal lasting at least 
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one minute. After quantifying the firefly luminescence, this reaction is 
quenched and the Renilla luciferase reaction is initiated simultaneously by 
adding Stop & Glo® Reagent to the same sample. Both assays can be 
completed in about 4 seconds using a luminometer with reagent auto- 
injectors. In the DLR™ Assay System, both reporters yield linear assays with 
attomole (<10–18) sensitivities and no endogenous activity in the experimental 
host cells. Furthermore, the integrated format of the DLR™ Assay provides 
rapid quantitation of both reporters either in transfected cells or in cell-free 
transcription/translation reactions. 
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Construct 
Number of 
constructs 
Reference 
HGMR1 1 Lee HJ et al. 2012 
GADD45 1 Takahashi S et al. 2001 
GDNF 1 Brodbeck S et al. 2004 
WISP-2/CCNF 2 Fritah A et al. 2006 
IGFBP1 2 
Sutherland Lab, University of 
Dundee 
FOXO1 1 Essaghir A et al. 2009 
LKB1 3 Lützner N et al. 2012 
ILRB2 2 Verma VK et al. 2012 
MZF1 p55 1 Deng Y et al. 2013 
β-Catenin 3 Liu G et al. 2012 
FHRE 1 Addgene 1789 
GADD45 1 Addgene 8358 
ILR2 1 Addgene 10959 
ERE 1 Addgene 11354 
β-Catenin 1 Addgene 12456 
52 
 
Table 2.5| Luciferase promoter reporter plasmids used in the dual-luciferase 
assay 
  
Axin2 1 Addgene 21275 
VEGFR2 1 Addgene 21306/21307 
STAT 1 Addgene 37392 
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2.5 Buffers and solutions 
Buffer Composition 
DNA Manipulation 
TAE buffer 
40mM TrisHCl, pH 8.0  
20mM acetic acid 
1mM EDTA 
DNA elution buffer 50mM TrisHCl, pH 8.0 
6X DNA Loading dye 
0.25% bromophenol blue 
0.25% xylene cyanol FF 
30% glycerol in water 
Protein purification 
Tissue Lysis Buffer 
25mM TrisHCl pH 7.4 
150mM NaCl 
1% NP40 
1mM EGTA 
1mM EDTA 
5mM sodium pyrophosphate 
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10mM β -glycerophosphate 
50mM sodium fluoride 
0.2mM PMSF 
1mM benzamidine 
1mM sodium orthovanadate 
0.1% 2mercaptoethanol 
270mM Sucrose 
1mM Microcystein 
SDS PAGE, Western blotting and agarose gels 
MOPS running buffer 
50mM MOPS 
50mM Tris Base 
0.1% SDS 
1mM EDTA, pH 7.7 
Transfer Buffer 
25mM Bicine 
25mM Bis Tris 
1mM EDTA 
TBS-T 10X 0.2 M Tris base pH 
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1.37M NaCl 
1% Tween 
Stripping buffer 
0.2M Glycine pH 2.2 
0.1% SDS 
Cell culture and cell based experiments 
PBS 
137mM NaCl 
2.7mM KCl 
4.3mM Na2HPO4 
1.47mM KH2PO4 
pH 7.4 
Cell Lysis Buffer 
25mM TrisHCl pH 7.4 
150mM NaCl 
1% NP40 
1mM EGTA 
1mM EDTA 
5mM sodium pyrophosphate 
10mM β glycerophosphate 
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50mM sodium fluoride 
0.2mM PMSF 
1mM benzamidine 
1mM sodium orthovanadate 
0.1% 2mercaptoethanol 
270mM Sucrose 
 
Table 2.6| Buffer and solutions. 
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Aim 
PTEN is a tumour suppressor gene that is found mutated in many human 
cancers. Most of its tumour suppressor activities and effects on gene 
expression appear related to its ability to inhibit the PI3- Kinase/AKT 
pathway and therefore suppress cell proliferation, survival and migration. 
Recent studies in our lab have shown that two mutants, PTEN Y138L and 
PTEN R308C, have the ability to control AKT activity but not cell migration 
and invasion. 
The aim of this project is to further understand how PTEN regulates 
tumourigenesis. To do this, two transgenic knock in mice lines were 
developed expressing PTEN Y138L and PTEN R308C mutants.  The aim of 
this work was to analyse the potential of these two mutants to lead to tumour 
formation and to influence embryo viability.  
In parallel, I have mined gene expression profiling data to investigate how 
PTEN and PTEN Y138L regulate gene expression. Luciferase promoter 
reporter assays were used to study genes whose transcription is regulated by 
PTEN. The goal of this latter work is to provide tools to easily reveal AKT-
dependent and AKT-independent transcriptional responses controlled by 
PTEN to investigate mechanisms by which PTEN controls cellular 
phenotype.  
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Chapter 3 
3. Results and Discussions 
3.1 Phenotypic analysis of Pten Y138L and 
R308C Knock In transgenic mice 
Mouse models of human cancer have played a vital role in understanding 
tumorigenesis and answering experimental questions, like interactions 
between cancer and normal cells in vivo, that other systems cannot address. 
Advances continue to be made that allow better understanding of the 
mechanisms of tumour development, and therefore the identification of better 
therapeutic and diagnostic strategies. Many research groups have used mice 
models to reconstruct in vivo the effects of PTEN loss and mutations on 
tumour development and cancer progression. These studies confirm that 
PTEN plays a critical role in cancer development, and genetic background 
may influence the onset, the spectrum, and the progression of tumorigenesis 
caused by Pten mutation (Di Cristofano, Pesce et al. 1998); (Podsypanina, 
Ellenson et al. 1999); (Suzuki, Yamaguchi et al. 2001); (Freeman, Lesche et 
al. 2006); (Wang, Karikomi et al. 2010).  
Most of the tumour suppressor activities of PTEN have been mainly attributed 
to its ability to dephosphorylate lipid substrates and thereby regulate 
signalling downstream of AKT. Despite the huge potential of both the 
phosphatase activities of PTEN, either by regulating PI3K effecting AKT or 
other pathways, such as RAC1, and by dephosphorylating heterolougous 
substrates, like FAK and SRC, understanding mechanisms that are 
independent from AKT inhibition has been an understudied area of research 
and it seems that the studies of PTEN’s ability to metabolise PtdIns(3,4,5)P3 
and regulate AKT have dominated PTEN research for the last decade. 
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A recent work published in our lab has shown that lipid and protein 
phosphatase activities are both required for PTEN to regulate several 
biological processes such as cell migration, cellular invasion and to mediate 
most of its largest effects on gene expression. Through whole-genome 
microarray analysis, there were analyzed changes of gene expression 
occurring in U87MG cells grown in 3D cultures transduced with the different 
forms of PTEN grown (Tibarewal, Zilidis et al. 2012). Using the information 
from the studies on TPTE and TPIP, our group conducted a mutagenic screen 
to identify a PTEN mutant, which selectively lacks activity against peptide 
substrates. Within the mutagenic screen, the Tyrosine at the 138 position, was 
mutated to Leucine to get the PTEN Y138L mutant. Phosphatase assays 
revealed that this mutant lacked detectable activity against polyGluTyr(P) but 
retained activity against PtdIns(3,4,5)P3. When expressed in PTEN null cells, 
PTEN Y138L was capable of reducing the levels of cellular PtdIns(3,4,5)P3 
and phospho-AKT as efficiently as wild type PTEN. Consistent with this were 
observed effects on downstream substrates of AKT including GSK3 and the 
ability of PTEN Y138L to supress cell proliferation in a soft-agar colony 
formation assay that was also similar to the wild type enzyme. However, 
PTEN Y138L was impaired in the regulation of some processes that wild-
type PTEN can inhibit, including invasion and control of epithelial 
morphology.  
Although the PTEN mutant Y138L was identified in a systematic mutagenic 
screen, it shows the same features of a mutant found in two human cancer 
samples, PTEN Y138C. This mutant is characterized by the substitution of 
the Tyrosine at the 138 position with a Cysteine and it was found in a human 
endometrial carcinoma sample and a lung cancer cell line – NCIH96 cells. 
Previous studies in the lab have shown that another mutant, PTEN R308C 
shared the same features with PTEN Y138L and Y138C. It is able to control 
AKT activity and cell migration in vitro but is unable to control epithelial 
morphogenesis and cellular invasion of glioma cells, DBTRG and U373 cell 
lines. PTEN R308C is a missense mutation characterized by the substitution 
of the Arginine at the 308 position with a Cysteine located in the so-called 
Dloop of PTEN. It was found in two different human tumour samples, a 
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glioma and a malignant uveal melanoma. PTEN R308C has both lipid and 
protein phosphatase activity and displays stability to wild-type PTEN in 
cultured U87MG cells. 
Having established in cultured cells that these two cancer-related mutations 
show partial loss of function compared to WT PTEN protein, this lead our lab 
to generate two Knock In transgenic mouse lines that express PTEN Y138L 
and PTEN R308C respectively. The reason to develop the two transgenic 
mouse lines was to further analyse how PTEN could regulate tumorigenesis 
in vivo and furthermore, if present, understand those pro-cancer mechanisms 
that are independent from AKT inhibition. 
3.1.1 Generation of Knock In Pten Y138L and Pten 
R308C Transgenic mice  
The two new transgenic mouse lines, Pten KI Y138L and Pten KI R308C 
were generated as a service by Taconic Artemis. They are constitutive Knock-
Ins of the point mutations (KI-PM) Pten Y138L and Pten R308C and the 
strategy used for the generation of them is described below. The targeting 
vectors were generated using BAC clones from the C57BL/6J RPCIB-731 
BAC library and transfected into the Taconic Artemis C57BL/6N Tac ES cell 
line. Through homologous recombination Y138L and R308C mutations were 
introduced into exon 5 and exon 8 of the Pten gene respectively, together with 
the positive selection marker (Puromycin resistance - PuroR) that was flanked 
by FRT sites and was inserted into intron 4 and intron 8 respectively. 
Homologous recombinant clones were then isolated using positive (PuroR) 
and negative (Thymidine kinase - Tk) selection. The constitutive KI-PM 
alleles were obtained after Flp-mediated removal of the selection marker. 
These KI-PM alleles express the mutated Pten Y138L and Pten R308C 
proteins, in particular the only difference from the native allele is each 
mutation and a single FRT site in the neighboring intron (Figure 3.1). 
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Figure 3.1| Sites of insertion of the two mutations for each transgenic line 
developed as a service by Taconic Artemis. a. The Y138L (AT>TG) mutation 
was introduced into exon 5 of Pten gene. b. The R308C (C>T) mutation was 
introduced into exon 8 of Pten gene. Green arrows correspond to FRT regions 
and the red boxes represent the two mutant exons, for Pten Y138L and Pten 
R308C respectively. 
  
62 
 
3.1.2 KI Y138L and KI R308C mice genotyping and 
PTEN gene sequencing  
In performing the in vivo characterization of these new Pten KI mice, I 
initially aimed to investigate two critical aspects: the presence of Pten Y138L 
and Pten R308C mutations in the correct sites and their effects on Pten protein 
stability.  
First, I wanted to be sure that any phenotypical change that I would have seen 
in the transgenic mice was due only to the presence of the mutations of our 
interest. First, to screen the mouse genotypes I have extracted DNA from all 
the transgenic mice in the breeding, from ear punches. I have then amplified 
the gene and performed a PCR in order to get the genotype of the mice. Both 
the KI Pten mutant are about 50 base pairs (bp) more than Pten WT gene 
because of the presence of two flanking regions of the PuroR and FRT. The 
PuroR site was removed after being used during the generation of the mice as 
selection marker. The difference in dimension of the PCR products allowed 
me to distinguish if the mouse was expressing two alleles of WT Pten 
(homozygous mouse, one single band of 250bp), one allele of WT Pten and 
one of KI Pten mutated gene (heterozygous mouse, two bands at 300 bp and 
200 bp) or two alleles of KI Pten mutated gene (homozygous mouse, one 
single band of 300bp). To confirm that this PCR product size-based 
genotyping assay reflected the presence of the relevant point mutation, I 
directly sequenced the expressed mRNA of Pten from three mouse liver 
samples. 
This also allowed me to check that there were no other mutations within the 
Pten gene other than our KI mutations of interest that could influence the 
phenotype of the mice. RNA was isolated from the liver of KI Pten Y138L 
and KI Pten R308C mice and, after amplifying the Pten gene through PCR I 
have sequenced the gene using the Sequencing Service of the University of 
Dundee (Figure 3.2).  
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Figure 3.2| Genotyping gels of Pten gene amplified from DNA samples 
released  from transgenic mice ears biopses for KI Y138L(a) and KI R308C 
(b) and sequencing of Pten -exon5 for Y138L (a) mutation and Pten -exon8 
for R308C(b) mutation amplified from cDNA of respective mice liver tissues. 
Electropherograms show expression of both Pten wt and Pten mutated alleles  
64 
 
From the sequencing of the Pten gene from three mice per line, I could verify 
that for both KI Pten Y138L and KI Pten R308C only the missense mutation 
inserted during the generation of the mice was present. This result gave me 
confidence that all the analysis and experiments conducted with the new 
cancer mouse models, both in vivo and ex vivo, would allow me to further 
understand how Pten Y138L and Pten R308C themselves could influence and 
regulate tumorigenesis in vivo. 
Also, since many PTEN missense point mutations render PTEN unstable 
(Lee, Yang et al. 1999), I measured the mutant Pten proteins levels in our Pten 
KI mice. I decided to analyze healthy tissues from aged matched mice (3 
males and 3 females from 38 to 42 days old) from the 6 transgenic mice 
groups in our breeding. Brain tissues samples were dissected, snap frozen and 
later homogenized in lysis buffer. Pten expression was analyzed in Western 
Blot for 3 mice per group (Figure 3.3). 
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Figure 3.3| a. Healthy brain tissues were dissected post-mortem from Pten 
WT (WT/WT), Pten Null (-/WT), Pten Hypomorph (Hypo/WT), KI Pten 
Y138L (YL/WT) and KI Pten R308C het (RC/WT) and hom mice (RC/RC). 
Pten expression was investigated by western blotting of tissues lysates using 
specific antibodies. b. Percentage of Pten expression normalized on Gapdh in 
mice brain tissues samples analysed in WB related to Pten WT expressing 
mice. Error bars show STD, n=3. 
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In the figure is shown one representative experiment out of 3, while the 
quantification data are related to 3 independent experiments of tissue samples 
from 3 mice for each group. These results show that both the KI Pten mutants 
are expressed in healthy tissues even though with a less amount of protein 
compared to WT Pten. The quantification analyses revealed that Pten R308C 
is expressed in heterozygosis, about 70-80%, and homozygosis, about 95%, 
when compared to WT Pten expressing mice, set as 100%. Pten Y138L may 
be expressed in heterozygosis, about 70% compared to Pten WT expressing 
mice, but, without the presence of samples from mice carrying the Y138L 
mutation in homozygousis, I would need other analysis in order to confirm 
the expression of the Pten Y138L mutant in het mice. For this reason, there 
were generated by Dr. Priyanka Tibarewal Mouse Embryonic Fibroblast 
(MEFs) cell lines from embryos of different genotypes, including Pten 
YL/WT and YL/YL. Experiments carried in MEFs will be described later in 
the thesis. The reduced expression of Pten Y138L and Pten R308C, compared 
to the WT protein, could be related to less stability of the mutants that could 
lead to a decreased expression of the proteins.  
3.1.3 Pten Y138L and Pten R308C analysis of 
influence in embryos viability 
To examine the role of PTEN in ontogenesis and tumour suppression, the 
groups of Pandolfi, Mak, Parsons and Wu each developed transgenic mice 
characterized by the disruption of mouse Pten expression on different genetic 
background. (Di Cristofano, Pesce et al. 1998); (Podsypanina, Ellenson et al. 
1999); (Suzuki, Yamaguchi et al. 2001); (Freeman, Lesche et al. 2006); 
(Wang, Karikomi et al. 2010). In all models, Pten inactivation resulted in 
early embryonic lethality, at different stage of the pregnancy (E7.5, E9.5, 
E6.5 and E9.5 respectively). Indeed Pten –/– ES cells formed aberrant 
embryoid bodies and displayed an altered ability to differentiate into 
endodermal, ectodermal and mesodermal derivatives (Di Cristofano, Pesce et 
al. 1998). Futhermore in vivo models of Cowden and Bannayan–Riley–
Ruvalcaba (BRR) syndromes were developed generating transgenic Knock In 
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mice expressing three sentinel alleles representing PTEN mutants identified 
in patients with Cowden syndrome: the nonsense PTEN ∆4–5 and missense 
PTEN C124R and PTEN G129E. PTEN ∆4–5 is a very unstable protein 
fragment whose expression cannot even be detected and is catalytically 
inactive.  The missense PTEN C124R is a catalytically inactive mutant, 
instead, while PTEN G129E mutation causes selective loss of activity against 
PtdIns(3,4,5)P3 it is stable and keeps the ability to metabolise peptide 
substrates. All the mutations resulted in early embryonic lethality and mutant 
homozygous embryos were recovered at embryo day (E) 8.5 and E9.5, also 
with lower than expected frequency. In particular the development of the few 
mutant homozygous embryos was severely compromised, with defects in 
anterior-posterior patterning, failure of axial rotation, and absence of overt 
tissue differentiation leading to resorption by E9.5 Wang, Karikomi et al. 
(2010). 
Previous transgenic mouse model lacking Pten or expressing or PTEN 
mutants resulted to be embryonic lethal (Di Cristofano, Pesce et al. 1998) 
(Trotman, Niki et al. 2003); (Wang, Karikomi et al. 2010). Also, mice 
expressing reduced [hypomorphic] level of Pten affected homozygous 
embryos viability, causing a reduction in the numbers of expected 
homozygous mice born (Trotman, Niki et al. 2003). Ever since these findings, 
I first evaluated the effect of Pten Y138L and Pten R308C on embryonic 
development by examining offspring derived from intercrosses between 
heterozygous Pten Y138L mice and between Pten R308C knock in mice 
(Table 3.1). The intercrosses have yielded no live homozygous progeny at 
birth for the Pten Y138L mutant. It seems likely that this is due to embryonic 
lethality of Y138L homozygous mice. Instead homozygosity of the Pten 
R308C mutant transgene did not affect the viability of the embryos. Indeed 
this analysis reveals a normal mendelian pattern within the R308C offspring 
composed of 50% heterozygous Pten R308C mice and for 25% each by 
homozygous Pten R308C mice and WT Pten mice. 
 
 
68 
 
 
Transgenic 
line 
  Heterozygous 
(+/m) 
Homozygous 
mutant 
(m/m) 
Homozygous 
Wild Type 
(+/+) 
Total 
KI Y138L observed 
expected 
183 
127 
0 
63.5 
72 
63.5 
254 
KI R308C observed 
expected 
80 
88 
45 
44 
51 
44 
176 
 
Tables 3.1|. The genotype of offspring from KI Pten Y138L and KI Pten 
R308C heterozygous intercrosses was determined by PCR. 1. Expected 
mendelian ratio and observed genotype in KI Pten Y138L and KI Pten R308C 
offsprings are shown.  
 
  
69 
 
3.1.4 In vivo tumorigenesis analysis of KI Pten Y138L 
and KI Pten R308C mice 
It was previously demonstrated that PTEN is a bona fide haploinsufficient 
TSG, whereas subsequent studies have shown that a decrease of PTEN dosage 
below normal leads to an accelerated progression to invasive cancer with a 
variable onset about 8-17 months of age for Pten +/- mice, 12-22 months for 
Pten hy/+ mice and 5-15 months for Pten hy/- mice (Trotman, Niki et al. 
2003), (Alimonti, Carracedo et al. 2010). Pten knock in mice expressing the 
three mutants PTEN ∆4–5, Pten C124R and Pten G129E alleles display 
distinct tumor phenotypes in organs targeted by Cowden syndrome with 
peculiar spectrum of tumours and severity (Wang, Karikomi et al. 2010). 
Moreover, cancer-related mutations PTEN C124S and PTEN G129E, induce 
acceleration of tumorigenesis in Knock In mice. They specifically act by 
further lowering Pten activity rather than engaging alternative pathways. 
They inhibit the WT protein function in trans in a dominant- negative manner, 
possibly as a result of heterodimerization. In turn, this reduced Pten lipid-
phosphatase activity leads to Akt hyperactivation and increased 
tumorigenesis in mice. (Di Cristofano, Pesce et al. 1998); (Podsypanina, 
Ellenson et al. 1999); (Stambolic, Tsao et al. 2000); (Trotman, Niki et al. 
2003), (Alimonti, Carracedo et al. 2010); (Wang, Karikomi et al. 2010); Papa, 
Wan et al. 2014). 
To investigate the tumorigenic potential of PTEN Y138L and PTEN R308C 
mutants, I have established an aging cohort of 60 mice for 6 groups of 
transgenic mice. These groups are KI Pten Y138L mice WT/YL, KI Pten 
R308C mice WT/RC KI Pten R308C RC/RC, Pten Null heterozygotes WT/-
, Pten Hypomorph heterozygotes WT/Hypo and Wild-Type mice. All the 
transgenic mice are on C57BL6 background. Mice that do not develop evident 
tumours are aged until they reached 700 days old, at that point animals are 
culled and internal organs (including spleen, liver, kidneys, adrenals, uterus, 
ovaries, prostate, heart, lungs, brain, gut) are analyzed by 
immunohistochemistry (IHC). If symptoms are identified suggesting hat an 
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animal has a tumour, they are immediately culled and internal organs are 
analyzed both in Immunohistochemistry and biochemistry.  
 
Table 3.2| Current state of tumourigenic analyses of PTEN Null het, PTEN 
Hypomorph het, KI Y138L het, KI R308C het and hom mice in comparison 
with Pten WT expressing mice 
The Pten Hypomorphic line is characterized by an insertion of a Neomycin 
cassette between the exons 3 and 4 that causes a decrease of 40% of Pten 
expression relative to a single wild-type gene copy. In heterozygosis the 
amount of Pten expressed in tissues is about 70-80% when compared to Pten 
WT expressing mice (Trotman, Niki et al. 2003). 
I decided to keep the Pten Hypomorphic transgenic line in the in vivo 
experiments because it represents a good control for our mouse models. 
Indeed, since even a little reduction in Pten expression could lead to tumour 
formation, and having showed that the two KI mutants are slightly less 
expressed than WT Pten, it was important to have a control that could 
reproduce the slight reduction of Pten expression. In this context, the 
difference that I have seen between our mouse models and the Pten 
Hypomorph mouse model gave me the confidence that they were occurring 
not only because of the reduced expression of KI Pten mutants but mainly 
because of the partial loss of function of Y138L and R308C, of which I have 
already speculated above. 
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Figure 3.4| Kaplan-Meier plot for percent survival in the aging cohort of the 
transgenic mouse lines: PTEN WT (Pten WT/WT), PTEN Null het (Pten 
WT/-), PTEN Hypo het (Pten WT/Hypo), KI Pten Y138L het (Pten WT/YL), 
KI Pten R308C het (Pten WT/RC) and KI Pten R308C hom (Pten RC/RC).  
n, number of mice analyzed. 
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In agreement with published data, 60 out of 60 Pten Null WT/- mice 
developed spontaneous tumours, mostly lymphadenomas, with an onset 
between 4 and 13 months old (Trotman, Niki et al. 2003). At the current stage, 
27 out of 60 KI Y138L WT/YL mice have developed tumours, suggesting 
that PTEN Y138L is tumorigenic per se and its expression has implications 
in tumour formation. Notably, the pattern of tumour formation between the 
Pten Null and the KI Pten Y138L line appeared to be very different. In the 
Pten Null line the major site of tumorigenesis were the lymph nodes and only 
few mice developed tumours in the gut area and in the prostate. Instead, 
Y138L tumour bearing mice, while having tumours formed in their lymph 
nodes, they showed also an interesting pattern that was more towards the 
development of tumours in the gut area, involving organs like intestine, liver 
and pancreas. Having not seen this peculiar tumour formation pattern in the 
control transgenic mouse line, this result suggests that it could be related to 
specific features of Pten Y138L. Instead, currently 10 R308C het mice have 
developed tumours, mainly involving the lymph nodes and tumours in the gut 
area, with an onset between 7 and 22 month of age. 
The majority of the mice in the Pten Hypomoprhic group have not reached 
the age that has been described as beginning of tumour growth, previously 
published by Trotman et al to be as 17-23 months of age (Trotman, Niki et al. 
2003). The oncogenic potential of Pten R308C mutant in homozygosis is still 
under investigation (Table 3.2) nevertheless one mouse had developed 
tumours at the age of 400 days. 
3.2 Characterization of KI Pten Y138L 
3.2.1 Pten Y138L mutant influences embryos viability 
In order to understand at what stage of the pregnancy the Y138L homozygous 
embryos died, I had stopped the pregnancies and embryos were dissected at 
the embryo day (E) 8.5, 9.5, 10.5, 12.5 and 16.5 and genotyped those through 
PCR (Table 3.2). No homozygous Pten Y138L embryo was found at the 
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embryo day (E) 10.5, 12.5 and 16.5, suggesting that the mutation affects the 
early development of the embryos involving the first 10 days of Instead, when 
there were genotyped embryos from day (E) 8.5 and 9.5, a few homozygous 
embryos were found in both the litters (Table 3.2). This supported the 
hypothesis that the homozygous embryos were dieing between E9.5 and 10.5 
days of pregnancy. Furthermore, after dissections of litters from E8.5, 9.5 and 
10.5, pictures of the embryos were taken by Dr Nadege Poncet. The pictures 
in Figure 3.5 show embryos of the genotypes Pten WT/WT, WT/Y138L and 
Y138L/Y138L from different stage of the pregnancy: E8.5, 9.5 and 10.5. The 
homozygous Y138L embryos were not properly developed in all the stages 
analysed. Interestingly, at E8.5 embryos were still alive independently from 
the genotype and E9.5 it was possible to detect heart beating from Pten 
Y138L/Y138L expressing mice. Instead, homozygous Pten Y138L embryos 
at E10.5 were not alive. In particular they were unable to properly form a fold 
that, after the gastrulation period will become the coelemic fold, and later the 
end of the alimentary canal. 
 
Table 3.3| Y138L E8.5, E9.5, E10.5, E12.5 and E16.5 were genotyped, 
expected mendelian ratio and observed genotype in KI Y138L offspring are 
shown  
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Figure 3.5| Pten Y138L embryos at E8.5, E9.5, E10.5, were dissected out and 
genotyped. Pictures of embryos were taken post dissections.  
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In mouse, blastocyst formation occurs at embryo day 4, E4. At E4.5, 
implantation occurs and the zona pellucida is discarded and the blastocyst 
attaches to uterine wall. The process of gastrulation begins at about E6.5 in 
the mouse and by E8 the primitive ectoderm of the post-implantation 
blastocyst generates the ectoderm, mesoderm, and endoderm of the gastrula. 
These and other complex processes result in the formation of the tissues and 
organs that occur in an adult mammal. They require the activation and 
inactivation of specific genes at specific times, highly integrated cell-cell 
interactions, and interactions between cells and their non-cellular 
environment, the extracellular matrix. In general, the embryonic ectoderm 
gives rise to the following tissues: CNS and outer surface or skin of the 
organism. The embryonic mesoderm gives rise to skeletal muscles, heart, 
blood and other connective tissues and the lining of the body cavity. The 
endoderm, gives rise to the epithelium of the entire digestive tract, epithelium 
of the respiratory tract, structures associated with the digestive tract (Liver 
and Pancreas), epithelium of the reproductive ducts and glands. Besides 
somatic cells, germ cells are also formed during the development of embryo. 
At E9 there are the first signs of radial asymmetry, during the pre-streak there 
is an advanced endometrial reaction: the blood starts to invade the 
ectoplacental cone and the extraembryonic ectoderm and embryonic axis are 
now becoming visible. By E10, during the Mid-Streak stage the amniotic fold 
starts to form and by the Late-Streak/Early stage the allantoic bud first 
appears (Lee, Jeong et al. 2007).  
Therefore at E.9.5 and E10.5 during the gastrulation period, which correspond 
to the Theiler Stages from 14 to 17, there occur the main developmental 
changes within the embryos that will determine if the embryos would survive 
and born. It is likely that Y138L mutation may be involved in the disruption 
of these developmental passages that could determine the lethality of 
homozygous embryos at E9.5-E10.5. In particular, homozygous Y138L 
embryos at E8.5 and E9.5 were unable to properly form a fold that, after the 
gastrulation period will become the coelemic fold, and later the end of the 
alimentary canal. 
76 
 
3.2.2 Ex-vivo investigation of PI3K /Akt activation 
Pathway in KI Pten Y138L mice 
Understanding PTEN functions that are independent from AKT inhibition has 
been an understudied area of research. Most of the past studies on PTEN’s 
protein phosphatase activity have relied on the PTEN mutant G129E which 
selectively retains activity against peptide substrates and lacks significant 
PtdIns(3,4,5)P3 phosphatase activity. Using the information from the studies 
on TPTE and TPIP within a the mutagenic screen, the Tyrosine at the 138 
position, essential for PTEN protein phosphatase activity, was mutated to 
Leucine to get the PTEN Y138L mutant. Phosphatase assays revealed that 
this mutant lacked detectable activity against polyGluTyr(P) but retained 
activity against PtdIns(3,4,5)P3. When expressed in PTEN null cells, PTEN 
Y138L was capable of reducing the levels of cellular PtdIns(3,4,5)P3 and 
phospho-AKT as efficiently as wild type PTEN.  
In order to understand if the ability to dephosphorylate lipid substrates and 
consequently to inhibit Pi3-Kinase/ Akt pathway was maintained in vivo, I 
decided to analyzed healthy tissues from aged matched young mice (3 males 
and 3 females from 38 to 42 days old) from the 6 transgenic mice groups. 
Tissues samples (included brain, liver, heart, thymus, prostate, skeletal 
muscle and spleen) were dissected snap frozen and lysed in a buffer 
containing protein phosphatase inhibitor, detergents and reducing agents. 
Samples from all the tissues of Wild Type Pten expressing mice were first 
analyzed in Western Blot to optimize blotting conditions and Pten level of 
expression and activation of Akt and its downstream effector were evaluated 
(Figure 3.6).  
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Figure 3.6| Tissues were dissected post-mortem from Pten WT expressing 
mice. Pten expression, phosphorylation of Akt and downstream targets were 
investigated by western blotting of brain tissues lysates using total and 
phospho-specific antibodies.  
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Next step was to further analyze Pten expression level in other normal tissues 
and from the results obtained in the experiments described above I choose to 
study in Western Blot samples from liver and spleen (Figure3.7).  
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Figure 3.7| a. Healthy tissues (Respectively: a.1 Liver; a.2 Spleen) tissues 
were dissected post-mortem from Pten WT (WT/WT), Pten Null  (-/WT), 
Pten Hypomorph (Hypo/WT) and KI Pten Y138L (YL/WT). Pten expression 
was were investigated by western blotting of tissues lysates using specific 
antibodies. b. Percentage of Pten expression in mice pre-neoplastic tissues 
(Respectively: b.1 Liver; b.2 Spleen) samples analysed in WB related to Pten 
WT expressing mice. Error bars show STD, n=3. 
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In the figure is shown one experiment out of 3 per tissue, while the 
quantification data are related to 3 independent experiments of tissue samples 
from 2 mice for each group. In agreement with previous shown results, Pten 
Y138L is slightly less expressed than Pten WT, with a percentage that was 
about 70-80% in both the preneoplastic tissues liver (Figure 3.7 a) and spleen 
(Figure 3.7 b).  
Furthermore, aiming to study the activation of Akt and the effectors of the PI-
3K pathway in preneoplastic tissues from Pten WT, PTEN -/WT, PTEN 
Hypomorph WT/Hypo, and KI Pten Y138L WT/YL I have performed 
Western Blot analysis of brain, liver and spleen from all the transgenic lines 
listed above.  
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Figure 3.8| Liver tissues were dissected post-mortem from Pten WT 
(WT/WT), Pten Null  (-/WT), Pten Hypomorph (Hypo/WT) and KI Pten 
Y138L (YL/WT). Pten expression, phosphorylation of Akt and downstream 
targets were investigated by western blotting of brain tissues lysates using 
total and phospho-specific antibodies.  
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Unfortunately, the results were found to be very variable from experiment to 
experiment. It is already published that the Pten WT/- expressing transgenic 
mice should be characterized by a higher activation of AKT and its 
downstream effectors, compared to Pten WT/WT expressing mice Di 
(Cristofano, Pesce et al. 1998). Instead, in my experiments such increases in 
the phosphorylation of Akt and S6 were modest or absent. These results are 
despite having performed all the lysing procedure of the tissue samples on ice 
using pre-chilled instruments and added a consistent amount of phosphatase 
inhibitor to the lysis buffer. One of the possible explanations is that the period 
of time between dissection and freezing of the samples was not short enough 
to avoid dephosphorylation before freezing and homogenization. Indeed, 
temperature is one of the most important features that could influence 
phosphorylation status of proteins. An example of one of these experiments 
is shown in Figure 3.8, although the patterns in phosphorylation observed 
were not consistently seen in all experiments.  
Despite the extensive analyses conducted, there were no clear results 
regarding difference of activation or expression of specific downstream 
effector of Akt among the samples from mice with different Pten genotype. 
The huge variability between samples expressing the same Pten genotype, 
due to the difficulty of working with tissues, has limited the interpretation of 
the data precluding a proper conclusion.  
3.2.3 In-vitro investigation of PI3K /Akt activation 
Pathway in MEFs 
Activation of oncogenes or inactivation of tumour suppressor pathways can 
result in neoplastic transformation. Animal models with altered expression of 
oncogenes or tumour suppressors have been established to address the role of 
these genes in tumorigenesis and provide a molecular basis for cancer 
therapy. Primary mouse embryonic fibroblast (MEF) cells represent a well-
defined cell type that has been instrumental in studying the consequences of 
gene-ablation in cellular growth and proliferation. Moreover, the ability to 
transform MEFs with oncogenes and their response to growth arrest triggers 
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has been well characterized. Thus, MEF cells derived from such mutant mice 
have proven to be an invaluable tool to study immortalization, transformation, 
and tumorigenesis. (Hong Sun and Reshma Taneja, Cancer genomics and 
proteomics 2007). 
To further analyze the tumourigenic potential of Pten Y138L, stable and 
immortalized MEF cell lines were derived from Pten transgenic mice by Dr 
Priyanka Tibarewal in our lab in order to have an in vitro stable transgenic 
cell model that express only the mutant proteins and allow me to analyze Pten 
protein function. Including the necessary control MEF cell lines, there were 
derived MEFs with different Pten genotypes:  
• Pten WT/WT (100% expression of WT Pten) 
• Pten -/- (0% expression of WT Pten) 
• Pten WT/-  
• Pten WT/Hypo  
• Pten Hypo/Hypo 
• Pten WT/Y138L (one allele expressing WT Pten and one expressing 
Pten Y138L) 
• Pten Y138L/- (only one allele expressing Pten Y138L) 
MEFs with decreasing dose expression of Pten WT were derived in order to 
have a control that could mimic the predisposition to tumour development 
seen in vivo due to a strong but also a subtle reduction of Pten expression 
(Trotman et al 2003, Alimonti et al 2010). Furthermore, these MEF lines 
represent also an indispensable tool for study the transgenic mouse lines that 
are part of the in vivo experiment aimed to analyse the tumorigenic potential 
of Y138L compared to the two control transgenic mouse lines PTEN Null and 
PTEN Hypomorph.  
  
84 
 
 
 
Figure 3.9| Pten WT/WT, -/-, -/- treated with 500nM PI3K inhibitor Pi103, -
/WT, WT/Hypo, WT/Y138L, -/Y138L, Hypo/Hypo expressing Mouse 
Embryo Fibroblassts were analysed in Western Blot. Pten expression, 
phosphorylation of Akt and downstream targets were investigated by western 
blotting of tumour lysates using total and phospho-specific antibodies. Pten 
WT/WT expressing Mefs were used as positive control. 
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Experiments carried out in the MEF cell lines, showed that the reduction of 
Pten expression level resulted in an up regulation of Akt phosphorylation, 
when compared with Pten WT expressing MEF cell line. Interestingly, MEF 
cell lines expressing 50% of Pten Y138L and 50% of PTEN WT or with only 
one allele of the mutant were able to control the activation of Akt and its 
downstream pathway. This result correlate with previous findings obtained in 
our lab and gave me more confidence that the phenotype show by our mouse 
model expressing one allele of Y138L is related to an independent pathway 
from Akt activation and will need more investigation. 
3.2.4 Ex vivo investigation of PI3K/Akt activation 
Pathway of Lymphoadenomas developed in mice 
Although the PTEN mutant Y138L was identified in a systematic mutagenic 
screen, it shows the same features as a mutant found in two human cancer 
samples, PTEN Y138C. This mutant is characterized by the substitution of 
the Tyrosine at the 138 position with a Cysteine and it was found in a human 
endometrial carcinoma sample and a lung cancer cell line. These findings 
suggested that those mutations are cancer-related mutations. Previously 
described results (Table 3.2 and figure 3.4) have revealed clearly the 
tumorigenic potential of Pten Y138L in mice, indeed it is tumorigenic per se 
and its expression has implications in tumour formation. 
I performed a pilot experiment to investigate Pten expression level and 
activation of PI3K pathway within the tumours spontaneously developed in 
mice. I have analysed lysates of two lymphoadenomas grown in Pten Null 
mice and two in Pten Y138L expressing mice (Figure 3.10). 
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Figure 3.10| Neck Lymphomas were dissected post-mortem from Pten -/WT 
and YL/WT expressing mice. Pten expression, phosphorylation of Akt and 
downstream targets were investigated by western blotting of tumour lysates 
using total and phospho-specific antibodies. Pten WT/WT expressing Mefs 
were used as positive control. 
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The results from this experiment are not consistent because it was done only 
once, but they could reveal that in contrary of Pten Null tumours, in Y138L 
driven lymphoadenomas there was a better expression of PTEN. In addition, 
in PTEN Y138L driven tumours, in this single experiment, it is visible a 
decrease in the expression of total mTOR and FOXO1 compared to Pten WT/- 
expressing tumours.  
3.3 Characterization of KI PTEN R308C 
Previous studies in the lab have shown that another mutant, PTEN R308C 
shared the same features with PTEN Y138L. It’s able to control AKT activity 
and cell migration in vitro but is unable to control epithelial morphogenesis 
and cellular invasion of U87MG cells. R308C mutation is a missense 
mutation located in the so called Dloop of PTEN characterized by the 
substitution of the Arginine at the 308 position with a Cysteine. It was found 
in two different human tumour samples, a glioma and a malignant uveal 
carcinoma. It has both lipid and protein phosphatase activity and it didn’t 
affect the stability of the PTEN protein in cultured cells. 
At the current stage of our experiment aiming to investigate the tumorigenesis 
in the KI mouse models, 10 KI Pten R308C het mice have developed tumours, 
mainly involving the lymph nodes, with an onset between 7 and 22 month of 
age, while the oncogenic potential of Pten R308C mutant in homozygotes is 
still under investigation (Table 3.1).  
Although the tumourigenic potential of this mutant is still under investigation 
and it does not affect embryo viability, it was important to deeply investigate 
and uncover a potential phenotype caused by the expression of one or both 
alleles encoding Pten R308C.  
Recent reports on mice with systemic overexpression of the tumour 
suppressor Pten have expanded our understanding of its physiological 
functions. Pten over-expressing transgenic mice present increased energy 
expenditure, decreased adiposity, improved insulin sensitivity upon high-fat 
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feeding or with aging, and extended lifespan. This has led to new mechanistic 
insights about the role of PTEN in metabolism. Overexpression of Pten in 
mice results in reduced body weight, which appears to be a consequence of 
decreased cell number, while cell size remains intact. Similarly, a study in 
humans carrying germline mutations in PTEN, and thereby constitutive and 
systemic decreased PTEN activity, suggested a strong association between 
decreased PTEN and obesity, although it was also observed a great 
constitutive insulin sensitization. The observation that PTEN 
haploinsufficiency can be directly related with obesity in humans, agrees with 
the finding observed in mice showing that PTEN overexpression protects 
from obesity. (Ortega-Molina and Serrano 2013). 
Considering these recent findings, we considered that an interesting 
phenotype to investigate could have been the influence by PTEN R308C on 
mice metabolism and therefore their body weight.  
3.3.1 Mice body weight measurement and analysis 
To analyse if Pten R308C could influence mice body weight, KI Pten R308C 
mice expressing WT Pten WT/WT, KI Pten R308C mice WT/R308C, KI 
R308C R308C/R308C littermates and cage-mates were weighed weekly from 
55 to 124 days old (Figure 3.11).  
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Figure 3.11| Graph showing body weight weekly measurement of KI Pten 
R308C littermates and cage-mates KI R308C expressing Pten WT/WT (Wt, 
n= 9), Pten R308C WT/RC (Het, n= 14) and Pten R308C RC/RC  (Hom, n= 
9) of young mice from 55 to 124 days old. Error bars showing SEM. 
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Preliminary data suggested that KI Pten R308C heterozygous mice were 
characterized by an increase in the body weight when compared with Pten 
WT expressing mice at 55 days old (Figure 3.11). Indeed the percentage of 
variation compared to littermates Pten WT expressing mice was about 15%. 
However, when the mice were older, it seemed that, while female mice at 124 
days old kept being heavier than Pten WT expressing mice, at 124 days in the 
male mice Pten WT/Y138L mice were almost exactly the same weight as Pten 
WT mice (Figure 3.11).  
To clarify this possible effect, I decided then to increase the numbers of the 
mice that were weighed and analyze the weight of an increased number of 
with an age between 200 and 300 days old.   
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Figure 3.12| a. Graph showing 
body weight measurement of 
KI Pten R308C littermates and 
cage-mates KI R308C 
expressing Pten WT/WT (Wt, 
n= 9), Pten R308C WT/RC 
(Het, n= 14) and Pten R308C 
RC/RC (Hom, n= 9) of young 
mice 55 days old (a) and older 
KI R308C expressing Pten 
WT/WT (Wt, n= 25), Pten 
R308C WT/RC (Het, n= 51) 
and Pten R308C RC/RC (Hom, 
n= 10) mice between 200 and 
300 days old (b). Error bars 
showing SEM. 
 
A B 
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From this analysis, I could see a decrease in the body weight of homozygous 
Pten R308C mice compared to those expressing Pten WT.  Notably, this result 
was statistically significant with a p value of 0.019 (Figure 3.12) but the 
significance was not confirmed when the group was split in male and female 
(Figure 3.12 A and B), suggesting that the composition of the groups could 
influence the results.  
3.3.2 Mice adipose tissue deposit measurement and 
analysis 
One factor that could influence mice body weight is the accumulation or 
depletion of adipose tissue. An increase in the body mass usually reflects a 
higher adipose tissue accumulation that leads to an increase of body weight. 
For this reason, I checked if Pten R308C homozygous mice were 
characterized by depletion in the adipose tissues, including gonadal and 
retroperitoneal fat. Littermates and cage-mates mice studied as described in 
figure 3.11 were sacrificed at 200 days old and their fat mass in the gonads 
and in the area behind the peritoneum was weighed carefully (Figure 3.13). 
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Figure 3.13| Graphs showing adipose deposit measurement of Gonadal Fat 
and Retroperitoneal Fat of KI Pten R308C expressing Pten WT/WT (Wt, n= 
6), Pten R308C WT/RC (Het, n= 8) and Pten R308C RC/RC (Hom, n= 5) of 
200 days old mice. Error bars showing SEM.  
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Both gonadal and retroperitoneal fat seemed reduced in Pten homozygous 
mice compared to Pten WT expressing mice. Furthermore, the measurement 
of the gonadal fat might reveal a link between body weight and fat 
accumulation in the gonads (Figure 3.13).  
3.3.3 Mice body weight measurement and analysis, a 
deep investigation 
To be confident of the result above, I decided to increase the number of mice 
analysed. A larger group of mice, including KI Pten R308C mice expressing 
WT Pten WT/WT, KI Pten R308C mice WT/R308C, KI R308C 
R308C/R308C of an age between 200 and 300 days old, was weighted once 
and the data were added to the previous mice studied as in Figure 3.12 (Figure 
3.14). 
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Figure 3.14| a. Graph showing body weight measurement of older KI Pten R308C expressing 
Pten WT/WT (Wt, n= 44),  Pten R308C WT/RC (Het, n= 62) and Pten R308C RC/RC (Hom, 
n= 16) mice between 200 and 300 days old (b). Error bars showing SEM. 
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Interestingly, when increasing the number of mice analysed, the result above 
described was not confirmed. Indeed, the differences among the three 
genotypes seemed only to reflect a natural variability that is absolutely normal 
in live animals (Figure 3.14). In fact, in this second bigger group the female 
and male component was more homogeneous. These findings lead me to 
believe that the R308C mutant may not be involved in a different regulation 
of body weight compared to Pten WT.  
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3.4 In vitro study of regulation of gene 
expression by PTEN through luciferase 
promoter reporter assay 
Regulation of gene expression includes a wide range of mechanisms that are 
used by cells to increase or decrease the production of specific gene products 
(protein or RNA). Any step of regulation of gene expression may be 
modulated, from the DNA-RNA transcription step to post-translational 
modification of a protein, of which, one of the most important is the 
transcription initiation. Transcription is initiated at the promoter site, as an 
increase in the amount of an active transcription factor binds a target DNA 
sequence. Other proteins, known as "scaffolding proteins", bind other 
cofactors and hold them in place. DNA sequences far from the point of 
initiation, known as enhancers, can aid in the assembly of this "transcription 
machinery." 
Gene promoters are typically located upstream of the gene and can have 
regulatory elements several kilobases away from the transcriptional start site 
(enhancers). In eukaryotes, the transcriptional complex can cause the DNA to 
bend back on itself, which allows for placement of regulatory sequences far 
from the actual site of transcription. Eukaryotic RNA-polymerase-II-
dependent promoters can contain a TATA element (consensus sequence 
TATAAA), which is recognized by the general transcription factor TATA-
binding protein (TBP); and a B recognition element (BRE), which is 
recognized by the general transcription factor TFIIB. The TATA element and 
BRE typically are located close to the transcriptional start site (typically 
within 30 to 40 base pairs) (Levine M et al. 2003). 
It is not yet known the involvement of PTEN in gene expression regulation. 
A recent paper published from our laboratory identified a set of transcripts 
that are induced by PTEN in a manner that does not correlate with AKT. Since 
they are induced, those gene expression events may make an easily assayable 
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readout for an AKT-independent signalling pathway regulated by PTEN 
(Tibarewal, Zidilis et al, 2012 After a deep analyses of the results obtained, I 
focused my attention on those genes whose expression was more up-regulated 
only by WT PTEN and not by partial loss of function mutants (Table 3.4). 
 
Table 3.4| List of genes up-regulated by WT PTEN or PTEN Y138L 
(minimum 5-fold changes) and selected for further luc-reporters analysis. 
Data are obtained after analyzing microarray output of experiments 
performed in U87MG cells (Tibarewal et al. 2012).  
In order to look at easily assayable integrated biological outputs from multiple 
signalling inputs downstream of PTEN and in particular to study the less-
well-understood signalling mechanisms that correlate with tumour 
suppression more deeply, I decided to perform luciferase assays based 
experiments. Through luciferase promoter reporter assay, I wanted to 
compare the regulation of several genes already recognized as being 
downstream of the PTEN/ Pi3-Kinase pathway with these recently identified 
PTEN-regulated transcripts. Luciferase promoter reporters are characterized 
by the presence of the promoter, or part of it, of the gene of interest fused with 
the gene that codify for the Firefly Luciferase inserted in a vector that allow 
the expression of the external DNA in the cells.  
Luciferase reporter technology can be a powerful tool for this analysis 
because it gives unparalleled sensitivity, dynamic range, versatility and ease 
of use when investigating questions that involve gene regulation. Genetic 
reporters are used as indicators to study gene expression and cellular events 
coupled to gene expression.  
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Luciferase-based genetic reporter assays provide sensitive methods for 
assaying gene expression, enabling the accurate quantification of small 
changes in transcription resulting from subtle changes in biology, like 
pharmacological treatments of cells or expression of specific external 
proteins. 
The response of each gene promoter to the presence of WT PTEN and its 
mutant or to treatments with the PI 3-kinase inhibitor GDC0941 was deeply 
analyzed through a luciferase promoter reporter assays. Firstly, U87MG cells, 
that lack the expression of PTEN, were cultured in both 2D and 3D and 
transiently co-transfected, when needed, with WT PTEN or PTEN mutants 
and the luciferase promoter reporter plasmids correspondent to the genes of 
interest. Most of the luciferase plasmid reporters were kindly provided from 
scientists who had already used those for their research, while several ones 
were bought from Addgene. All the gene promoter reporters used are listed 
in the Material and Methods section (Table 2.5).  
3.4.1 Evaluation of the specificity of the Dual-
Luciferase® Reporter (DLR™) Assay  
The DLR™ Assay allows sequential measurement of Firefly luciferase 
followed by Renilla luciferase activity on addition of Stop & Glo® Reagent 
to the reaction. Both reporter activities were quantitated within the same 
sample of lysate prepared from either U87MG or DBTRG cells. 
Preliminary experiments were used to optimize the conditions of the assay 
and to test whether the reporters delivered assayable luciferase activity. 
HEK293 cells were cultured in adherence and transiently transfected with the 
luciferase promoter reporter plasmids. After 24 hours of transfection, cells 
were harvested and lysed and the expressed luciferase activity was measured 
trough a plate reader luminometer. Preliminary experiments were conducted 
to optimize the luciferase assays in terms of efficient transfection, optimal 
concentrations of plasmid DNA, volumes and concentrations of the lysates 
and setting of the gain for the luminometer used. The ratio between the 
100 
 
plasmid DNA of promoters of interests and the Renilla Reporter Control was 
kept to 20:1 in order to avoid interference from the Renilla’s luminescence 
signal into the Firefly luciferase’s signal and the settings of the lumonometer 
were set to maintain all the signals from the samples in the linear range of 
measurement. For some initial experiments, a problem was detected with the 
Renilla Luciferase plasmid used, seeming to deliver both Firefly and Renilla 
luciferase channel activities, but which was fixed by a replacement Renilla 
Luciferase plasmid. 
Optimized assay settings were then used to analyze the gene promoters in 
U87MG and DBTRG gliomas cells and their response to WT PTEN and other 
mutants of PTEN or the PI3K inhibitor GDC0941.  
Firstly, to assess the specificity of the assay and to be confident of the results, 
I carefully analysed the readout of the measurements of both Firefly and 
Renilla luciferases that the plate-reader luminometer detected in the samples.  
I transfected U87MG gliomas cells with 0.5 µM of a luciferase promoter 
reporter plasmid from the list in table 2.5 in the Material and Methods Chapter 
that showed robust activity, in the case shown in Figure 4.1 the reporter is the 
GADD45 promoter reporter gene, or 0.1 µM of the Renilla Luciferase 
Plasmid. Since Renilla luciferase is under the control of the strong promoter 
SV40, constitutively active and does not respond to cell environment, it is 
used in this assay as control for transfections efficiency, I have also co-
transfected U87MG cells with both luciferase promoter reporter plasmid and 
Renilla Luciferase plasmid (Figure 3.15). To be used as a transfection 
control, the Renilla luciferase plasmid includes the  strong constitutive 
promoter SV40 with no evidence of regulated, context dependent 
transcription. In order to avoid any trans-effect that could influence the 
specificity of the bioluminescence detected, following manifacturer’s 
instructions, I decided to set a ratio between Firefly Luciferase and Renilla 
Luciferase of 5:1. Indeed, it is possible to add relatively small quantities of a 
control reporter vector compared to the reporter plasmids of interest to 
provide low-level, constitutive expression of that luciferase control activity.  
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Figure 3.15| The graphs show one representative experiment out of many 
conducted in U87MG cells.  a. Firefly luciferase activity is detected in 
U87MG cells after 24 hours of transient transfection of the Luciferase 
Promoter Reporter GADD45 gene and the Renilla Luciferase plasmids 
together or individually transfected. b. Renilla Luciferase Activity detection 
in U87MG cells treated as in a. c. Calculation of the Ratio of luciferase 
activity (Firefly luciferase / Renilla luciferase) in the same samples as in a 
and b. Error bars show STD, n=3. 
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This experiment was repeated several times and with different luciferase 
promoter reporter plasmids.  The graph in figure 3.15 is a representative 
experiment to show that the luciferase activity was specific for both the 
GADD45 Firefly luciferase reporter and for the Renilla Luciferase plasmid. 
Indeed, in the samples transfected with the GADD45 gene promoter reporter, 
only the Firefly luciferase activity was specifically detected (Figure 3.15 a) 
along with a little activity detected also for Renilla luciferase which is 
probably due to carry over of unquenched Firefly luminescence into the 
Renilla’s measurement wavelength channel. Instead, in the samples in which 
only the Renilla reporter was introduced, only Renilla luciferase activity 
could be detected (Figure 3.15 b). Furthermore in the samples co-transfected 
with both the luciferase reporters I could detect both Firefly and Renilla 
activity and I could calculate the ratio between them (Figure 3.15). 
These results allowed me to proceed further with the analysis of the gene 
expression regulation by PTEN firstly in U87MG cells and later in DBTRG 
using co-transfected Renilla reports as internal controls. 
3.4.2 Promoter reporter analysis in U87MG cells 
The most known and recognized function of PTEN is counteracting the PI3K-
AKT pathway and acting, as a tumour suppressor. Having identified PTEN-
responsive genes in microarray expression analysis, we wanted to investigate 
the mechanisms by which this control is applied. I decided to treat U87MG 
cells with 1µM of the drug GDC-0941 which is a potent, selective, and orally 
bioavailable PI3K inhibitor currently in Phase II clinical trials against solid 
tumours and non-Hodgkin's lymphoma.  In particular, GDC-0941 is a potent 
inhibitor of p110α and p110δ (IC50 = 3 nM) (also less potently p110beta and 
p110gamma). It selectively binds to PI3K isoforms in an ATP-competitive 
manner, inhibiting the production of the secondary messenger 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the 
PI3K/AKT signaling pathway. 
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Alongside the analysis of the promoters of those genes found in our laboratory 
to be induced or suppressed by PTEN WT or Y138L, I decided to analyse the 
activity of the promoter of genes that are already recognized as being 
downstream of the PTEN/ PI3- Kinase pathway. 
U87MG cells were cultured in adherence transiently co-transfected with the 
Firefly luciferase promoter reporter plasmids together with the Renilla 
reporter control and after 12 hours of transfection cells were treated with the 
PI3-Kinase inhibitor GDC-0941. After 18 hours from the treatment, cells 
were harvested and the luciferase activity of each Firefly luciferase promoter 
reporter gene in lysates was measured through a plate reader luminometer 
(Figure 3.16). 
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Figure 3.16| a. The graph shows the luciferase activity expressed in U87MG cells after 24 hours of transient co-transfection of different 
promoter reporter plasmids and the Renilla luciferase reporter plasmid. Cells were treated for 18 hours with 1µM of the PI3K inhibitor 
GDC0941 or DMSO before performing the assay. The luciferase activity was analyzed using a plate reader that measures the 
bioluminescence intensity in each sample.  Intensity of Renilla Luciferase of each sample was used to normalize Firefly Luciferase 
activity. Error bars show STD, n=4. b. Western blot of U87MG cells co-transfected as in a. Phosphorylation of AKT and total protein’s 
expression were investigated were investigated by western blotting of cell lysates using total and phosphor-specific antibodies.  
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26 luciferase reporter fusion constructs were initially tested for their response 
to PI3K inhibition in U87MG cells. Although some reporters did not have a 
detectable luciferase activity, the experiment shown in Figure 3.16a revealed 
that some reporters responded to the treatment with GDC-0941 either by 
being induced or inhibited. Indeed, the graph shows one representative 
experiment out of three performed and shows the ratio between Firefly and 
Renilla luciferase activity of each reporter. In order to confirm that the 
inhibitor had affected the activation of the PI3K/AKT pathway, cells treated 
as described above, were lysed and the activation of AKT was analysed in 
Western Blot. As shown in Figure 3.16b, a decrease is clearly visible in the 
AKT phosphorylation on the 473 Serine residues in the sample treated with 
the PI3K inhibitor, compared to untreated cells. This strengthens our 
conclusion that the activation of the PI3K/AKT pathway was strongly 
inhibited after 18 hours of treatment with 1µM GDC-0941 and changes in the 
luciferase activity of the promoter reporter genes were dependent on this.  
By dephosphorilating PIP3, PTEN blocks the activation of the PI3K/AKT 
pathway and from this point of view, the effects could be similar to the 
treatment of cells with a PI3K inhibitor. For this reason I decided to screen 
the luciferase reporters also after the expression of PTEN in glial cells lacking 
of the expression of the tumour suppressor (Figure 3.17).  
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Figure 3.17| The graph shows the luciferase activity expressed in U87MG cells after 24 hours of transient co-
transfection of different promoter reporter plasmids and PTEN constructs or pCDNA3.1 Empty Vector and the 
Renilla Luciferase Reporter Plasmid. The luciferase activity was analyzed using a plate reader that measures the 
bioluminescence intensity in each sample. Intensity of Renilla Luciferase of each sample was used to normalize 
Firefly Luciferase activity. Error bars show STD, n=3. . Western Blot of U87MG cells co-transfected as in a.  PTEN 
expression and GAPDH as loading control were investigated by western blotting of cell lysates using specific 
antibodies.  
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U87MG cells were cultured in adherence, transiently co-transfected with the 
Firefly luciferase promoter reporter plasmids together with the Renilla 
reporter control. In addiction cells were also co-transfected with the empty 
vector pcDNA3.1 or the vector for the expression of PTEN WT. After 48 
hours from the transfection, cells were harvested, lysed and the luciferase 
activity of each Firefly luciferase promoter reporter gene was measured 
trough a plate reader luminometer (Figure 3.17). In order to verify the 
presence of PTEN protein after transfection, cells treated as described above 
were lysed and the expression of PTEN was analysed by Western Blotting. 
The blot in figure 3.17b shows that PTEN was expressed after the transient 
transfection; instead cells transfected with the empty vector did not have any 
PTEN expressed. The graph in figure 3.17 shows one representative 
experiment out of three performed presenting the ratio between Firefly and 
Renilla luciferase activity of each reporter. 
Although PTEN’s function is not limited to the inhibition of the AKT 
pathway and could affect cellular processes through AKT-independent 
mechanisms, from the results of this experiments I could discriminate that the 
effects seen for some of the reporters, after the treatment with GDC-0941, 
could correlates with the inhibition of AKT. Indeed, some reporters, including 
GADD45, FOXO1 and IGFBP1 revealed likely correlation with AKT 
inhibition and made me believe that the luciferase activity assayed in each 
samples was related to the state of activation of each promoter and their link 
with the PI3K/AKT pathway.  
3.4.3 Assay of selected promoter reporter’s activation 
after expression of PTEN WT and its mutants.  
PTEN is constitutively expressed in normal cells but under pathological 
conditions, PTEN levels can be dramatically reduced, indeed it has been 
found mutated in many primary and metastatic human cancers. In particular 
I focused my attention on the functionally selective mutant of interest PTEN 
Y138L and its control on gene expression compared to PTEN WT.  
108 
 
In order to see if an AKT-independent pathway could regulate the 
transcriptional regulation of genes of our interest, I wanted to investigate the 
effects on gene expression of PTEN Y138L compared to PTEN WT and 
PTEN C124S, which is a catalytic inactive mutant of PTEN. For this analysis 
I have selected 7 reporters that, in the previous experiment have shown a 
detectable and specific luciferase activity. I have selected both those whose 
behaviour appeared PI3K-dependent (like GADD45, FOXO1 and VGFR2) 
those, instead, who act differently to the treatment with the PI3K inhibitor or 
the expression of PTEN (like β-Catenin) and those, which not responded to 
the treatments (like GDNF) (Figure 3.18). 
In order to verify the presence of PTEN protein after transfection, cells treated 
as described above were lysed and the expression of PTEN was analysed in 
Western Blot. The blot in Figure 3.18b shows the expression of PTEN WT 
and its mutants after 48 hours of transfection. 
 
109
 
  
 
Figure 3.18| A selected representative experiment out of four. a. The graph shows the luciferase activity expressed in U87MG 
cells after 24 hours of transient co-transfection of selected promoter reporter plasmids and PTEN constructs or pCDNA3.1 
empty vector and the Renilla Luciferase Reporter Plasmid. The luciferase activity was analyzed using a plate reader that 
measures the bioluminescence intensity in each sample.  Intensity of Renilla Luciferase of each sample was used to normalize 
Firefly Luciferase activity. Error bars show STD, n=3. b. Western Blot of U87MG cells co-transfected as in a. PTEN 
expression and GAPDH as loading control were investigated by western blotting of cell lysates using specific antibodies.  
 
110 
 
The graph in figure 3.18 show one representative experiment out of four 
performed in U87MG cells and shows the ratio between Firefly and Renilla 
luciferase activity of each reporter. 
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Figure 3.19| T-test analysis of four independent experiments performed in 
U87MG cells as described in Figure 3.18. P values under 0.0083333 (*) were 
considered statistically significant. The Bonferroni correction was applied to 
set P level of significance to set the p value significance threshold. Six 
multiple comparisons were done. None of the comparisons were found to be  
statistically different.  Error bars show STD, n=4. 
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I have analysed the means of the luciferase activity of four independent 
experiments performed for each promoter reporter in multiple comparisons. 
From this analysis, I observed that the transfection of the empty vector, the 
catalytic inactive protein PTEN C124S and the catalytic active proteins PTEN 
WT or the mutant PTEN Y138L did not cause any considerable change in the 
activation of the reporter genes selected. The combinations that I have done 
are:  
• pCDNA3.1 vs PTEN WT 
• pCDNA3.1 vs PTEN C124S 
• pCDNA3.1 vs  PTEN Y138L 
• PTEN WT vs PTENC124S 
• PTEN WT vs PTEN Y138L 
• PTEN C124S vs PTEN Y138L 
For the statistical analyses, I applied the T-test, considering significant a p 
value less than 0.0083333. Since it included multiple comparisons I have 
applied the Bonferroni Correction to set the P value significance level. First I 
have decided a familywise significance threshold (0,05), then I have divided 
it for the numbers of comparisons that I was making (6). The result of this 
calculation was 0.0083333.  
The analyses revealed that there were no differences between the empty 
vector pCDNA3.1, the catalytic inactive protein PTEN C124S and the 
catalytic active protein PTEN WT or the partially active mutant PTEN Y138L 
(Figure 3.19).  This could be due to the sensitivity of the test that could not 
allow differencies among the groups to be revealed.  
It is known that FOXOs are key mediators of tumour suppression downstream 
of PTEN and play a critical role in regulating apoptosis Fu and Tindall (2008), 
but it is not well known if this regulation could be explained by the regulation 
of the transcription of the FOXO1 gene and if this process is or is not AKT 
dependent. To test the hypothesis that PTEN WT and PTEN Y138L could 
induce the transcriptional activation of the gene encoding FOXO1, I decided 
to analyse the expression of total FOXO1 protein in U87MG cells transduced 
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with lentiviruses in order to express PTEN WT or PTEN Y138L in a 
increasing dose expression. I have chosen to adopt transduction instead of 
transient transfection because the infection with lentiviruses could allow an 
efficiency of transduction about 90-100%, while with transient transfection I 
could only obtained the 30-40% of cells transfected and the percentage of 
untransfected cells could have influenced the result of the Western Blot by 
diluting the signal (Figure 3.20). 
  
114 
 
 
 
Figure 3.20 Western Blot of U87MG cells transduced with increasing doses 
of lentiviruses expressing PTEN WT or PTEN Y138L. PTEN, FOXO1 
expression and GAPDH as loading control were investigated by western 
blotting of cell lysates using specific antibodies.  
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Dr. Priyanka Tibarewal transduced U87MG cells with increasing amounts of 
lentiviruses for both PTEN WT and PTEN Y138L. Cells were lysed and 
protein extracts were analysed in western Blot. I have investigated the 
expression of PTEN along with the expression of total FOXO1. The blot in 
figure 3.20 shows that when the amount of PTEN protein expressed in the 
cells was increasing it caused also an increase in expression of FOXO1 in 
both the samples of cells transduced with PTEN WT and PTEN Y138L. In 
particular, the increase expression of FOXO1 promoted by PTEN WT was 
slightly higher compared with PTEN Y138L. It was observed in previous 
studies in the lab that PTEN Y138L is a less stable protein compared to PTEN 
WT or PTEN C124S. Because of this issue, I had to be very careful in 
interpreting the results; the results could also reflect the decrease of the 
expression of PTEN Y138L and not only its partial loss of function. 
It is important to investigate and deep study the activation and the 
expression’s regulation of those proteins in order to fully understand PTEN’s 
functions.  
3.4.4 Analysis of transcriptional promoter’s 
activation in 3D cells cultured  
Adding the third dimension to a cell’s environment creates significant 
differences in cellular characteristics and behaviour, compared to cells 
cultured as monolayers on hard surfaces. Importantly, these differences 
normally create a greater similarity between the cultured cells and the living 
organism (e.g. human being) the cells are meant to represent – leading to more 
useful data and more relevant research. In addition, previous studies in our 
lab had suggested that, culturing PTEN null cells in 2D or 3D cause several 
changes in cells behaviour including gene expression modifications. For this 
reason I decided to analyse the activation of the promoter of the genes of 
interest after 24 hours of 3D culture. For the three dimensional culture I had 
use a bilayer of matrigel in which U87MG cells were seeded forming the so 
called “sandwich” and culture medium was put on top in order to give the 
cells all the nutrients that they needed. 
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U87MG cells were cultured initially in 2D and transiently co-transfected with 
the Firefly luciferase promoter reporter plasmids together with the Renilla 
reporter control. In addiction cells were also co-transfected with the empty 
vector pcDNA3.1 or the vector for the expression of PTEN WT. After 18 
hours from transfection, cells were harvested and transferred in matrigel for 
3D culture. Cells were 3D cultured for 24 hours and after this period of time 
cells were lysed and the luciferase activity of each Firefly luciferase promote 
reporter gene was measured trough a plate reader luminometer (Figure 3.21). 
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Figure 3.21| The graph shows the luciferase activity expressed in U87MG cells cultured in 3D after 24 hours of transient co-
transfection of different promoter reporter plasmids and PTEN WT or pCDNA3.1 Empty Vector and the Renilla Luciferase 
Reporter Plasmid. The luciferase activity was analyzed using a plate reader that measures the bioluminescence intensity in each 
sample.  Intensity of Renilla Luciferase of each sample was used to normalize Firefly Luciferase activity. Error bars show STD, 
n=2.  
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The optimized Dual Luciferase Assay as it was for cells in 2D culture did not 
detect assayable Firefly or Renilla luciferase activity for all the promoter 
reporters analysed. Only few promoters had shown a ratio between Firefly 
and Renilla luciferase that was the result of reliable measurements, including 
βCatenin (Figure 3.21). The graph in figure 3.21 shows one representative 
experiment out of two performed in 3D cultured cells and bars represent the 
mean ratio of these promoter reporters. Although the results were not totally 
clear to be interpreted, it seemed that the activation of the promoters in 3D 
cultured cells reflected what was revealed from luciferase assays in 2D 
cultured cells (Figure 3.17). From these data, it appears that the activity of 
these gene promoters may not be dependent on the methodology of culture 
and so the 3D environment of the cells. It is necessary to better optimize the 
assay in terms of gain of the laser of the luminometer, concentrations of DNA 
used for the transfection and number of cells seeded in order to obtain reliable 
measurements that could be trusted and clearly interpreted. 
3.4.5 Screening of the luciferase activity of 
the gene promoter reporters in response to 
the inhibition of the PI3K/AKT signalling 
pathway in DBTRG cells 
A screening of the Firefly luciferase activity of the gene promoter reporters 
assayed in the experiments discussed above was performed using another 
PTEN null glioma cell line, DBTRG. The main reason for doing that was to 
validate the results obtained using U87MG cells and the specificity of the 
Firefly luciferase activity assayed in response to the inhibition of the 
PI3K/AKT pathway.  
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DBTRG cells were treated as U87MG cells (Figure 3.16). Cells were 
cultured in 2D, transiently co-transfected with the Firefly luciferase promoter 
reporter plasmids together with the Renilla reporter control and after 12 hours 
of transfection cells were treated with the PI3-Kinase inhibitor GDC-0941.  
After 18 hours of the treatment, cells were harvested, lysed and the luciferase 
activity of each Firefly luciferase promoter reporter gene was measured 
trough a plate reader luminometer (Figure 3.22).The graph in Figure 3.22 
shows an experiment performed in DBTRG cells.  
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Figure 3.22| The graph shows the luciferase activity expressed in DBTRG cells after 24 hours of transient co-transfection 
of different promoter reporter plasmids and the Renilla Luciferase reporter plasmid. Cells were treated for 12 hours with 
1µM of the PI3K inhibitor GDC0941 or DMSO (Untreated) before performing the assay. The luciferase activity was 
analyzed using a plate reader that measures the bioluminescence intensity in each sample.  Intensity of Renilla Luciferase 
of each sample was used to normalize Firefly Luciferase activity. Error bars show STD, n=2. b. Western Blot of DBTRG 
cells co-transfected as in a. Phosphorylation of AKT and total protein’s expression were investigated were investigated 
by western blotting of cell lysates using total and phosphor-specific antibodies.  
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The same culturing transfection and luciferase assay conditions were used as 
in the experiments performed in U87MG cells. Unfortunately not for all the 
gene promoter reporters analysed was detected a reliable value, due probably 
to the different cell model. Indeed, further optimization steps may be needed 
in this cell line in order to obtain reliable results as the values of the Renilla 
luciferase, which is used as control, were not detected uniformly for all the 
samples and in some cases, Renilla activity was undetectable. This suggest 
that the ratio between the transfected Firefly luciferase reporter plasmids and 
the Renilla luciferase plasmid may need to be changed when assaying 
luciferase activity in DBTRG cells. However, many of the samples provided 
robust Renilla activity and data for many of the gene reporter seemed to 
behave as they did in U87MG. This result gave me confidence in the 
reliability of the findings highlighted above conducted using U87MG cells.  
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Chapter 4 
Conclusions 
The aim of this project was to further understand how PTEN regulates 
tumourigenesis. To do this, two transgenic knock in mice lines were 
developed expressing Pten Y138L and Pten R308C mutants. I could verify 
that for both the transgenic mouse line KI Pten Y138L and KI Pten R308C 
only the missense mutation inserted during the generation of the mice was 
present (Figure 3.2). Therefore, all the analysis and experiments conducted 
with the new cancer mouse models, both in vivo and ex vivo, allowed me to 
further understand how Y138L and R308C themselves could influence and 
regulate tumourigenesis in vivo. Notably, 27 out of 60 KI Pten Y138L 
WT/YL mice have developed tumours, suggesting that Pten Y138L is 
tumorigenic per se and its expression has implications in tumour formation. 
Pten Y138L tumour bearing mice, are characterized by tumours formed in 
their lymph nodes, which are very common in Pten +/- animals. They also 
showed an interesting pattern that was more towards the development of 
tumours in the gut area, involving organs like intestine, liver and pancreas. 
Having not seen this peculiar tumour formation pattern in the Pten +/- mouse 
line, this result suggests that it could be related to specific features of Pten 
Y138L. Instead, currently 10 Pten R308C het mice have developed tumours, 
mainly involving the lymph nodes, with an onset between 7 and 22 month of 
age, while the oncogenic potential of Pten R308C mutant in homozygosis is 
still under investigation (Table 3.2).  
It is already published that transgenic mouse model lacking Pten, or 
expressing a reduced [hypomorphic] level of Pten protein or inactive Pten 
mutants affected homozygous embryos viability. The analyses of the effect 
of Pten Y138L and Pten R308C on embryonic development revealed that Pten 
Y138L is embryonic lethal. In particular homozygous embryos died at the 
E9.5 day of pregnancy. Instead homozygosity of the Pten R308C mutant 
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transgene did not affect the viability of the embryos (Table 3.1).  The 
homozygous Pten Y138L embryos were not properly developed in all the 
stages analyzed. It is likely that Pten Y138L mutation may be involved in the 
disruption of these developmental events that could determine the lethality of 
homozygous embryos at E9.5-E10.5. Indeed, at E9.5 they were not alive and 
they were unable to properly form a fold that, after the gastrulation period 
will become the coelemic fold, and later the end of the alimentary canal 
(Figure 3.5). 
In order to avoid difficulties due to inter-samples variability of frozen tissue 
and to study the PI3K pathway activation in mouse, experiments were carried 
out in the MEF cell lines, showing that the reduction of Pten expression level 
resulted in an up regulation of Akt phosphorylation, when compared with 
Pten WT expressing MEF cell line. Interestingly, MEF cell lines with only 
one allele of the mutant were able to control the activation of Akt and its 
downstream pathway. This result correlate with previous findings obtained in 
our lab and gave me more confidence that the phenotype show by our mouse 
model expressing one allele of Pten Y138L is related to an independent 
pathway from Akt activation and will need more investigation. 
Although the tumourigenic potential of Pten R308C is still under 
investigation and it does not affect embryo viability, I investigated a potential 
phenotype caused by the expression of one or both alleles encoding Pten 
R308C. An interesting phenotype to investigate could have been the influence 
by Pten R308C on mice metabolism and therefore their body weight. The 
results obtained lead me to believe that the Pten R308C mutant may not be 
involved in a different regulation of body weight, compared to Pten WT. In 
fact, when increasing the number of mice analysed, the differences among the 
three genotypes seemed only to reflect a natural variability that is absolutely 
normal in live animals (Figure 3.14). It will need more investigation in order 
to reveal and assess a phenotype that could characterized the in vivo 
expression of the mutant, either in homozygosis or in heterozygosis.  
A better knowledge about these two PTEN mutants, PTEN Y138L and PTEN 
R308C is therefore critically clinical important. Firstly because the two 
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mutations are both related to human cancers and secondly because they cause 
a partial loss of function of PTEN that could not be AKT-dependent. Analyses 
using these mice should also allow us to understand the mechanisms by which 
these mutants promote tumour development and test whether we can make 
predictions about how to match particular patients with drugs to help inform 
cancer treatment decisions. 
In parallel, I have mined gene expression profiling data to investigate how 
PTEN and Y138L mutant of PTEN regulate gene expression. A recent paper 
identified a set of transcripts that are induced by PTEN in a manner that does 
not correlate with AKT. Since they are induced, those gene expression events 
may make an easily assayable readout for an AKT-independent signalling 
pathway regulated by PTEN (Tibarewal, Zilidis et al. 2012). Luciferase 
promoter reporter assays were used to study genes whose transcription is 
regulated by PTEN. The goal of this latter work is to provide tools to easily 
reveal AKT-dependent and AKT-independent transcriptional responses 
controlled by PTEN to investigate mechanisms by which PTEN controls 
cellular phenotype. Along side the analysis of the promoters of those genes 
found in our laboratory to be induced or suppressed by PTEN WT or Y138L, 
I decided to analyze the activity of the promoter of genes that are already 
recognized as being downstream of the PTEN/PI3-Kinase pathway. Although 
PTEN’s function is not limited to the inhibition of the AKT pathway and 
could affect cellular processes through AKT-independent mechanisms, from 
the results of this experiments I could discriminate that the effects seen for 
some of the reporters, after the treatment with GDC-0941, correlated with the 
inhibition of AKT.  
The reporter that revealed to be interesting was the luciferase reporter of the 
promoter of FOXO1. In fact, PTEN Y138L was observed to cause a weaker 
activation of the promoter of FOXO1 compared with PTEN WT (Figure 
3.20). This result could be due either to the less expression of the mutant or 
to the partial loss of function of PTEN Y138L and then, to an AKT-
independent mechanism. In particular, when the amount of PTEN protein 
expressed in the cells was increasing it caused also an increase in expression 
of FOXO1 in both the samples of cells transduced with PTEN WT and PTEN 
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Y138L. In particular, the increase expression of FOXO1 promoted by PTEN 
WT was slightly higher compared with PTEN Y138L. Taken together, these 
findings suggest that PTEN WT is a strong regulator of transcriptional level 
of FOXO1 and that, PTEN Y138L may have a defect in inducing FOXO1 
expression that could be AKT-independent and due to its partial loss of 
function. This result revealed an important task that should be  investigated 
further.  
Both the research projects described in the thesis could help us understanding 
how PTEN suppresses tumour formation in vivo and regulates gene 
expression in a way not dependent from AKT.  These findings will also help 
inform cancer treatment decisions matching patients with treatments 
accordingly to their mutational pattern of PTEN.  
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